<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27716773</article-id><article-id pub-id-type="pmc">5055331</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0163697</article-id><article-id pub-id-type="publisher-id">PONE-D-16-13046</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Thrombin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Epithelial Cells</subject><subj-group><subject>Endothelial Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Biological Tissue</subject><subj-group><subject>Epithelium</subject><subj-group><subject>Epithelial Cells</subject><subj-group><subject>Endothelial Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Biological Tissue</subject><subj-group><subject>Epithelium</subject><subj-group><subject>Epithelial Cells</subject><subj-group><subject>Endothelial Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Chaperone Proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Recombinant Proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Molecular Development</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cell Physiology</subject><subj-group><subject>Cell Fusion</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Physiology</subject><subj-group><subject>Growth Factors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Endocrine Physiology</subject><subj-group><subject>Growth Factors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Endocrine Physiology</subject><subj-group><subject>Growth Factors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cell Motility</subject><subj-group><subject>Chemotaxis</subject><subj-group><subject>Chemokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Enhanced Mitogenic Activity of Recombinant Human Vascular Endothelial Growth Factor VEGF<sub>121</sub> Expressed in <italic>E</italic>. <italic>coli</italic> Origami B (DE3) with Molecular Chaperones</article-title><alt-title alt-title-type="running-head">Enhanced Mitogenic Activity of Recombinant VEGF<sub>121</sub> Expressed with Molecular Chaperones</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kaplan</surname><given-names>Ond&#x00159;ej</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Z&#x000e1;rubov&#x000e1;</surname><given-names>Jana</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mikulov&#x000e1;</surname><given-names>Barbora</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="author-notes" rid="currentaff001"><sup>&#x000a4;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Filov&#x000e1;</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>B&#x000e1;rtov&#x000e1;</surname><given-names>Ji&#x00159;ina</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ba&#x0010d;&#x000e1;kov&#x000e1;</surname><given-names>Lucie</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brynda</surname><given-names>Eduard</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Institute of Macromolecular Chemistry, Czech Academy of Sciences, CZ-162 06, Prague, Czech Republic</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Institute of Physiology, Czech Academy of Sciences, CZ-142 20, Prague, Czech Republic</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Faculty of Science, Charles University in Prague, CZ-128 40, Prague, Czech Republic</addr-line></aff><aff id="aff004"><label>4</label><addr-line>School of Dental Medicine, General University Hospital in Prague, CZ-128 08, Prague, Czech Republic</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Thomas</surname><given-names>Jean-L&#x000e9;on</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Yale University School of Medicine, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>
<list list-type="simple"><list-item><p><bold>Conceptualization:</bold> OK JZ.</p></list-item><list-item><p><bold>Formal analysis:</bold> OK EF.</p></list-item><list-item><p><bold>Funding acquisition:</bold> LB EB EF.</p></list-item><list-item><p><bold>Investigation:</bold> OK JZ LB.</p></list-item><list-item><p><bold>Methodology:</bold> OK BM JZ EF JB.</p></list-item><list-item><p><bold>Project administration:</bold> LB EB EF.</p></list-item><list-item><p><bold>Supervision:</bold> LB EB.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> OK JZ LB.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> OK LB.</p></list-item></list>
</p></fn><fn fn-type="current-aff" id="currentaff001"><label>&#x000a4;</label><p>Current address: Institute of Microbiology, Czech Academy of Sciences, CZ-142 20, Prague, Czech Republic</p></fn><corresp id="cor001">* E-mail: <email>ondrej.kaplan@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>7</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>10</issue><elocation-id>e0163697</elocation-id><history><date date-type="received"><day>4</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Kaplan et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Kaplan et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0163697.pdf"/><abstract><p>We describe the production of a highly-active mutant VEGF variant, &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>, which contains a substrate sequence for factor XIIIa at the aminoterminus designed for incorporation into a fibrin gel. The &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> gene was synthesized, cloned into a pET-32a(+) vector and expressed in <italic>Escherichia coli</italic> Origami B (DE3) host cells. To increase the protein folding and the solubility, the resulting thioredoxin-&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> fusion protein was co-expressed with recombinant molecular chaperones GroES/EL encoded by independent plasmid pGro7.</p><p>The fusion protein was purified from the soluble fraction of cytoplasmic proteins using affinity chromatography. After cleavage of the thioredoxin fusion part with thrombin, the target protein was purified by a second round of affinity chromatography. The yield of purified &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was 1.4 mg per liter of the cell culture. The &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> expressed in this work increased the proliferation of endothelial cells 3.9&#x02013;8.7 times in comparison with commercially-available recombinant VEGF<sub>121</sub>. This very high mitogenic activity may be caused by co-expression of the growth factor with molecular chaperones not previously used in VEGF production. At the same time, &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> did not elicit considerable inflammatory activation of human endothelial HUVEC cells and human monocyte-like THP-1 cells.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Grant Agency for Health Research of the Czech Republic</institution></funding-source><award-id>15-29153A</award-id></award-group><award-group id="award002"><funding-source><institution>BIOCEV &#x02013; the Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University</institution></funding-source><award-id>CZ.1.05/1.1.00/02.0109</award-id><principal-award-recipient>Ondrej Kaplan</principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Technology Agency of the Czech Republic</institution></funding-source><award-id>TA04011345</award-id></award-group><award-group id="award004"><funding-source><institution>Ministry of Education, Youth and Sports of the Czech Republic</institution></funding-source><award-id>EE2.30.0029</award-id></award-group><funding-statement>This work has been supported by the Ministry of Education, Youth and Sports of the Czech Republic (Grant No. EE2.30.0029 and by National Sustainability Program II Project BIOCEV-FAR LQ1604), by the BIOCEV project (CZ.1.05/1.1.00/02.0109), by the Agency for the Czech Republic Health Research, Ministry of Health of the Czech Republic (Grant No. 15-29153A), and by the Technology Agency of the Czech Republic (grant No. TA04011345).</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="22"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Therapeutic angiogenesis is a promising approach for treating patients with cardiovascular diseases, and is also critical in engineering vascularized tissue replacements. Vascular endothelial growth factor (VEGF) plays an essential role in regulating normal and pathological angiogenesis and vascular permeability. VEGF promotes the adhesion and growth of vascular endothelial cells, which can be used advantageously for endothelialization of cardiovascular implants, such as small-diameter vascular replacements [<xref rid="pone.0163697.ref001" ref-type="bibr">1</xref>] or endovascular stent grafts [<xref rid="pone.0163697.ref002" ref-type="bibr">2</xref>], and for vascularization of various three-dimensional porous scaffolds for tissue engineering [<xref rid="pone.0163697.ref003" ref-type="bibr">3</xref>]. VEGF-A is one of five members of the VEGF family, along with VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF) [<xref rid="pone.0163697.ref004" ref-type="bibr">4</xref>&#x02013;<xref rid="pone.0163697.ref007" ref-type="bibr">7</xref>].</p><p>The VEGF-A gene consists of a 14-kb coding region organized in eight exons separated by seven introns [<xref rid="pone.0163697.ref008" ref-type="bibr">8</xref>]. The first four exons encode the signal peptide, the sequences of recognition by the VEGF receptors, and the dimerization and glycosylation site. Exon 5 encodes a sequence of ten amino acids that contains the main site of cleavage by plasmin and matrix metalloproteinases [<xref rid="pone.0163697.ref009" ref-type="bibr">9</xref>]. Exons 6 and 7 encode two heparin-binding domains [<xref rid="pone.0163697.ref010" ref-type="bibr">10</xref>]. Due to alternative exon splicing, a large number of VEGF isoforms exist. The most notable in humans are VEGF<sub>121</sub>, VEGF<sub>165</sub> and VEGF<sub>189</sub>. The number indicates the amino acids in the mature polypeptide after removal of the signal sequence [<xref rid="pone.0163697.ref011" ref-type="bibr">11</xref>]. These isoforms are distinguished by the presence or absence of the peptides encoded by exons 6 and 7. VEGF<sub>121</sub> lacks both heparin-binding domains, and is therefore diffusible. VEGF<sub>165</sub> lacks exon 6. VEGF<sub>189</sub> contains both heparin-binding domains, and is tightly associated with the cell surface or the extracellular matrix [<xref rid="pone.0163697.ref012" ref-type="bibr">12</xref>]. VEGF<sub>165</sub> and VEGF<sub>189</sub> might be released from the extracellular matrix (ECM) by plasmin, both directly through digestion of the components of the basement membrane and indirectly by activating collagenases from zymogens [<xref rid="pone.0163697.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0163697.ref013" ref-type="bibr">13</xref>]. Cleavage of VEGF<sub>165</sub> and VEGF<sub>189</sub> by plasmin results in VEGF<sub>110</sub> [<xref rid="pone.0163697.ref012" ref-type="bibr">12</xref>], which is highly diffusible. VEGF<sub>110</sub> is biologically and biochemically similar to alternatively spliced VEGF<sub>121</sub> [<xref rid="pone.0163697.ref014" ref-type="bibr">14</xref>].</p><p>The impact of different VEGF-A isoforms on the development and patterning of the vascular system has also been supported by genetic studies using isoform-specific knockouts in mice. Fifty percent of the mice expressing exclusively VEGF<sub>120</sub> (mouse VEGF-A is one amino acid shorter than human VEGF-A) died soon after birth, and showed impaired cardiac performance and myocardial angiogenesis [<xref rid="pone.0163697.ref015" ref-type="bibr">15</xref>]. VEGF<sub>120/120</sub> mouse embryos also exhibited a specific decrease in capillary branching, which was probably caused by changes in the extracellular localization of VEGF-A. Endothelial cells were preferentially integrated within existing vessels to increase the lumen caliber, rather than being recruited into newly-formed branches. However, mice expressing only VEGF<sub>188</sub> displayed abnormally thin vessel branches. Half of the mice died between embryonic stage E9.5 and E13.5 [<xref rid="pone.0163697.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0163697.ref017" ref-type="bibr">17</xref>]. Mice expressing only VEGF<sub>164</sub> had no abnormalities [<xref rid="pone.0163697.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0163697.ref019" ref-type="bibr">19</xref>]. The angiogenic activity of VEGF-A in tissues is thus regulated by different affinity of VEGF-A isoforms from the ECM, and by processing of VEGF-A and ECM by proteases and heparinases. Longer forms of VEGF-A might represent a storage form of the growth factor that is released after degradation of the ECM, while the diffusible forms play a more dynamic role and are readily available to endothelial cells [<xref rid="pone.0163697.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0163697.ref021" ref-type="bibr">21</xref>].</p><p>Due to the critical role of VEGF-A in promoting neovascularization, clinical trials have investigated the administration of VEGF-A as a recombinant protein or gene [<xref rid="pone.0163697.ref022" ref-type="bibr">22</xref>]. The results of phase I trials using intravenous or intracoronary infusions were typically encouraging [<xref rid="pone.0163697.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0163697.ref026" ref-type="bibr">26</xref>]. However, the results obtained in the larger phase II trials failed to prove that there was a significantly more beneficial effect than for the placebo group [<xref rid="pone.0163697.ref027" ref-type="bibr">27</xref>]. These disappointing clinical results have been attributed in part to the biological half-life of intravenously administrated VEGF-A, which is less than 30 min [<xref rid="pone.0163697.ref028" ref-type="bibr">28</xref>]. Owing to the high instability of the protein, large doses and multiple injections would be needed, but these might lead to pathological vessel formation at non-target sites [<xref rid="pone.0163697.ref029" ref-type="bibr">29</xref>]. This demonstrated the need to optimize the delivery method for VEGF-A. One way to improve the delivery and the stability of VEGF-A in the body may be by immobilizing the growth factor into a polymer matrix, where the release can be controlled by the degradation rate of the polymer.</p><p>In this study, we prepared a mutant variant &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>, first designed by Zisch et al. [<xref rid="pone.0163697.ref030" ref-type="bibr">30</xref>], containing a substrate sequence (NQEQVSPL) for factor XIIIa that would enable covalent incorporation of VEGF<sub>121</sub> into the fibrin network. VEGF-loaded fibrin matrices have been shown to increase the growth activity of vascular endothelial cells [<xref rid="pone.0163697.ref030" ref-type="bibr">30</xref>]. They can therefore be used for coating vascular prostheses or other cardiovascular implants (stents, heart valve replacements) in order to accelerate their endothelialization. To improve its folding and solubility, the protein was expressed in fusion with thioredoxin. Linkage of the gene of interest to a second 'carrier' or 'partner' gene avoids the problems associated with heterologous protein expression in <italic>E</italic>. <italic>coli</italic> [<xref rid="pone.0163697.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0163697.ref032" ref-type="bibr">32</xref>]. Glutathione-S-transferase, maltose-binding protein, thioredoxin and NusA have been successful in producing correctly folded and soluble recombinant proteins in bacteria [<xref rid="pone.0163697.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0163697.ref033" ref-type="bibr">33</xref>].</p><p>Thioredoxin (Trx) has been shown to facilitate the soluble expression of a number of mammalian growth factors and cytokines [<xref rid="pone.0163697.ref034" ref-type="bibr">34</xref>]. It is a small, ubiquitous protein that is involved in many physiological functions, and acts both intra- and extracellularly [<xref rid="pone.0163697.ref035" ref-type="bibr">35</xref>]. It works as an important antioxidant that plays a key role in maintaining the reducing environment in the cells. Outside the cell, however, thioredoxin acts as a growth factor or cytokine and stimulates angiogenesis [<xref rid="pone.0163697.ref035" ref-type="bibr">35</xref>&#x02013;<xref rid="pone.0163697.ref037" ref-type="bibr">37</xref>]. In mammalian cells, thioredoxin is encoded by two Trx genes. The Trx1 isoform occurs in the cytosol and nucleus, while the Trx2 isoform is expressed in the mitochondria. Homozygous knock-out of either isoform in mouse was found to be lethal [<xref rid="pone.0163697.ref037" ref-type="bibr">37</xref>]. Thioredoxin of <italic>E</italic>. <italic>coli</italic> encoded by the TrxA gene is a single polypeptide chain composed of 109 amino acid residues with a molar weight of 11.7 kDa, and is structurally related to human thioredoxin.</p><p>Besides fusion with thioredoxin, a combination of pET-32a(+) vector and <italic>E</italic>. <italic>coli</italic> Origami B(DE3) host cells was chosen to increase the soluble protein fraction. This combination was used for several proteins that were difficult to express with a structure related to VEGF [<xref rid="pone.0163697.ref038" ref-type="bibr">38</xref>&#x02013;<xref rid="pone.0163697.ref040" ref-type="bibr">40</xref>].</p><p>In the present study, protein folding was encouraged by co-expression with recombinant molecular chaperones GroES/EL encoded by independent plasmid pGro7. The &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> prepared by the strategy presented here had a 3.9&#x02013;8.7 times greater effect on endothelial cell proliferation than commercially-available VEGF<sub>121</sub>. Since the final &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> preparation probably contained a small amount of thrombin, which was used for cleavage of the fusion partner and which is able to stimulate the proliferation of endothelial cells [<xref rid="pone.0163697.ref041" ref-type="bibr">41</xref>&#x02013;<xref rid="pone.0163697.ref043" ref-type="bibr">43</xref>], the effect of appropriate concentrations of thrombin on endothelial cell proliferation were also observed. In addition, VEGF can cause immune activation of cells, which can even lead to implant rejection [<xref rid="pone.0163697.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0163697.ref045" ref-type="bibr">45</xref>]. We therefore also tested the potential of VEGF to induce the production of pro-inflammatory cytokines and chemokines in human vascular endothelial cells and human monocyte-like THP cells.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>Materials</title><p>pET-32a(+) plasmid and <italic>E</italic>. <italic>coli</italic> Origami B (DE3) host cells were obtained from Merck KGaA, Germany. Chaperone plasmid pGro7 was supplied by Takara Bio Inc., Japan. Talon Metal Affinity Resin was purchased from Clontech, USA. Recombinant vascular endothelial growth factor VEGF<sub>121</sub> variants expressed in <italic>E</italic>. <italic>coli</italic> (VEGF<sub>121</sub>
<bold>I</bold>; Cat. No. CYT-343) and in mammalian HEK cells (VEGF<sub>121</sub>
<bold>II</bold>; Cat. No. CYT-116) came from Prospecbio, USA. The VEGF<sub>121</sub>-ELISA Kit was purchased from Invitrogen, USA. A Cell Proliferation Kit II (XTT) was obtained from Roche, Switzerland. Human Umbilical Vein Endothelial Cells (HUVECs), EBM-2 Basal Medium and EGM-2 SingleQuots were supplied by Lonza, Czech Republic. Concentration cell Amicon Ultra (cut-off 10 kDa) and membrane filters (pore size 0.22 &#x003bc;m) were from Millipore, USA. Dialysis membrane Spectra/Por 6 (MWCO: 1000) was obtained from Spectrum Labs, USA. Coomassie Brilliant Blue R-250 was purchased from Serva, USA. Bradford reagent was from Bio-Rad, Germany. The SDS-PAGE molecular weight protein marker was supplied by GE Healthcare, UK. L-Arabinose, the Resazurin-based In Vitro Toxicology Assay Kit, human monocyte-like THP-1 cells, RPMI-1640 medium, lipopolysaccharides from <italic>E</italic>. <italic>coli</italic> 026:B6 and thrombin from human plasma were purchased from Sigma-Aldrich, Germany.</p></sec><sec id="sec004"><title>Construction of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> expression vector</title><p>The gene sequence encoding the modified variant of human VEGF<sub>121</sub> (&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>), which contains the additional factor XIIIa substrate sequence NQEQVSPL [<xref rid="pone.0163697.ref030" ref-type="bibr">30</xref>] at the aminoterminus of mature VEGF<sub>121</sub>, was synthesized by Generay Biotech, China, according to the published sequences (GenBank). The codon bias was optimized with respect to the <italic>E</italic>. <italic>coli</italic> preferred codon usage. The gene was subcloned between restriction sites <italic>Msc</italic> I and <italic>Xho</italic> I of the expression vector pET-32a(+) after the thioredoxin gene. The nucleotide sequence of the final construct (pET32-VEGF<sub>121</sub>) was confirmed by DNA sequencing.</p></sec><sec id="sec005"><title>Expression of Trx-&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub></title><p>The construct was used to transform <italic>E</italic>. <italic>coli</italic> Origami B (DE3) competent cells. The strain was co-transformed with the expression vector pGro7 encoding GroEL/ES chaperone genes. <italic>E</italic>. <italic>coli</italic> Origami B (DE3) cells were grown in 2YT medium (10 g of yeast extract, 16 g of tryptone, and 5 g of NaCl per liter; 200 mL in 500-mL Erlenmeyer flasks) with ampicillin (100 mg/L) and chloramphenicol (35 mg/L) in an orbital shaker for ca. 3 h at 37&#x000b0;C and at 220 rpm. When the OD at 600 nm reached a value of ca 0.5, isopropyl-&#x003b2;-D-thiogalactopyranoside (IPTG) was added to a final concentration of 0.02 mM, and the temperature was lowered to 25&#x000b0;C. The expression of GroEL/ES was induced by arabinose (1.7 g/L), which was added at the same time point as IPTG. After 20 h of incubation, the cells were washed with the buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 2.5 mM CaCl<sub>2</sub>), pelleted by centrifugation, and the pellets were stored frozen at -80&#x000b0;C until required.</p></sec><sec id="sec006"><title>Recombinant &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> purification</title><p>The harvested cells were then disrupted by sonication, and the cell debris was removed by centrifugation (13 000 rpm, 25 min, 4&#x000b0;C). The supernatant was loaded onto a Talon Metal Affinity Resin column equilibrated with the same buffer. After washing with washing buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 2.5 mM CaCl<sub>2</sub>, 1 mM imidazole), the recombinant protein was eluted with the same buffer containing 200 mM imidazole. The purified fusion protein Trx-&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was dialyzed against Tris buffer to remove imidazole, and then it was cleaved by human thrombin (9.5 NIH units/ mg of fusion protein, 4 h, RT). The cleaved thioredoxin fusion part was removed by a Talon Metal Affinity Resin column equilibrated with Tris buffer. The purified &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was analyzed by 12% SDS-PAGE followed by Coomassie Brilliant Blue staining.</p></sec><sec id="sec007"><title>Cell culture</title><p>Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in EBM-2 basal medium (Lonza, Cat. No. CC-3156), supplemented with EGM-2 SingleQuots (Lonza, Cat. No. CC-4176) containing 2% fetal bovine serum in a humidified air atmosphere with 5% CO<sub>2</sub> at 37&#x000b0;C.</p></sec><sec id="sec008"><title>Endothelial cell proliferation followed by the xCELLigence system</title><p>The effect of purified VEGF<sub>121</sub> on proliferation of the endothelial cells was evaluated by the xCELLigence System (Roche Applied Science). This device consists of microtiter plates containing interdigitated gold microelectrodes. This enables label-free, real-time monitoring of cell growth and viability based on electrical impedance measurements.</p><p>First, the E-plate background signal corresponding to the culture medium was set up. The E-plate was seeded with HUVEC cells (3 500 per well) in 150 &#x003bc;L EBM-2 basal medium supplemented with ascorbic acid, hydrocortisone, heparin, gentamicin, amphotericin-B and 2% fetal bovine serum from EGM-2 SingleQuots and different concentrations of recombinant &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> (20, 50, and 100 ng/mL) or commercial VEGF<sub>121</sub>
<bold>I</bold> and VEGF<sub>121</sub>
<bold>II</bold> as standards (20, 50, and 100 ng/mL). The hEGF, VEGF, R3-IGF-1 and h-FGF-beta that are also present in the SingleQuots supplement were not added into the EBM-2 basal medium. Cell growth was monitored every 15 minutes for up to 7 days.</p><p>To test the effect of thrombin on proliferation of the endothelial cells, the E-plate was seeded with HUVEC cells (3 500 per well) in 150 &#x003bc;L of EBM-2 basal medium with ascorbic acid, hydrocortisone, heparin, gentamicin, amphotericin-B and 2% fetal bovine serum from EGM-2 SingleQuots. Subsequently, the effect of thrombin (0, 0.01, 0.05, 0.1 and 1.0 NIH U/mL) on the proliferation of HUVEC cells in the presence of VEGF<sub>121</sub> standards (0, 20, 50 and 100 ng/mL) was monitored every 15 minutes for up to 7 days.</p></sec><sec id="sec009"><title>In vitro toxicology assay kit, resazurin-based</title><p>A resazurin 4 mM stock solution was filter-sterilized and stored at -20&#x000b0;C. Cell proliferation was observed for up to 7 days. On day 2, 4 and 7, the cells were twice washed with PBS and incubated in 4 &#x003bc;M resazurin diluted in EGM-2 culture medium without added growth factors for 4 hours at 37&#x000b0;C and 5% CO<sub>2</sub>. The relative cell count was quantified by fluorescence measurement (excitation 530 nm, emission 590 nm) on a Synergy HT Multi-Mode Microplate Reader (BioTek).</p></sec><sec id="sec010"><title>Protein concentration</title><p>The protein concentration was determined by the Bradford method [<xref rid="pone.0163697.ref046" ref-type="bibr">46</xref>] with bovine serum albumin (BSA) as the standard, or by the Human VEGF ELISA Kit (Invitrogen, #KHG0112), in accordance with the manufacturer&#x02019;s instructions.</p></sec><sec id="sec011"><title>Potential immune activation of cells by &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub></title><p>The pro-inflammatory potential of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was estimated by production of selected cytokines and chemokines (<xref ref-type="table" rid="pone.0163697.t001">Table 1</xref>) by HUVEC cells and by human monocyte-like THP-1 cells, derived from the peripheral blood of a one-year old boy with acute monocytic leukaemia (Sigma-Aldrich, Cat. No. 88081201).</p><table-wrap id="pone.0163697.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0163697.t001</object-id><label>Table 1</label><caption><title>Cytokines and chemokines used for estimation of the cell immune activation.</title></caption><alternatives><graphic id="pone.0163697.t001g" xlink:href="pone.0163697.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">Cytokine or chemokine</th><th align="justify" rowspan="1" colspan="1">Abbreviation</th><th align="left" rowspan="1" colspan="1">Characteristics</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">Interleukin-1&#x003b1;</td><td align="justify" rowspan="1" colspan="1">IL-1&#x003b1;</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Protein, cytokine</p></list-item><list-item><p>Produced by activated macrophages, neutrophils, epithelial cells, endothelial cells</p></list-item><list-item><p>Inductor of inflammation, fever, activator of TNF-&#x003b1;</p></list-item></list></td></tr><tr><td align="justify" rowspan="1" colspan="1">Interleukin-1&#x003b2;</td><td align="justify" rowspan="1" colspan="1">IL-1&#x003b2;</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Protein, cytokine</p></list-item><list-item><p>Produced by activated macrophages</p></list-item><list-item><p>Inductor of fever, inflammation, cell proliferation, differentiation, apoptosis</p></list-item></list></td></tr><tr><td align="justify" rowspan="1" colspan="1">Granulocyte macrophage colony-stimulating factor</td><td align="justify" rowspan="1" colspan="1">GM-CSF</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Glycoprotein, cytokine</p></list-item><list-item><p>Secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts</p></list-item><list-item><p>Stimulates production of granulocytes and monocytes</p></list-item></list></td></tr><tr><td align="justify" rowspan="1" colspan="1">Tumor necrosis factor-&#x003b1;</td><td align="justify" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Protein, cytokine</p></list-item><list-item><p>Produced by macrophages, lymphoid cells, mast cells, endothelial cells, cardiac myocytes, adipose tissue, fibroblasts, neurons</p></list-item><list-item><p>Inductor of inflammation, fever, apoptotic cell death, cachexia, inhibitor of tumorigenesis</p></list-item></list></td></tr><tr><td align="justify" rowspan="1" colspan="1">Monocyte chemoattractant protein</td><td align="justify" rowspan="1" colspan="1">MCP-1</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Protein, chemokine</p></list-item><list-item><p>Produced by endothelial, epithelial, smooth muscle, mesangial, astrocytic, monocytic and microglial cells, fibroblasts</p></list-item><list-item><p>Regulates migration and infiltration of monocytes/macrophages</p></list-item></list></td></tr><tr><td align="justify" rowspan="1" colspan="1">Interleukin-8</td><td align="justify" rowspan="1" colspan="1">IL-8</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Peptide, chemokine</p></list-item><list-item><p>Produced by macrophages, epithelial cells, airway smooth muscle cells, endothelial cells</p></list-item><list-item><p>Induces chemotaxis in granulocytes, angiogenesis, histamine production</p></list-item></list></td></tr></tbody></table></alternatives></table-wrap><p>THP-1 cells were seeded at a concentration of 10 000 cells per well in a 24-well cell culture plate (TPP, Switzerland) in the RPMI-1640 medium (Sigma-Aldrich, Cat. No. R6504) supplemented with 10% fetal bovine serum (Sigma-Aldrich, Cat. No. F7524), sodium bicarbonate (Sigma-Aldrich, Cat. No. M4892), and gentamicin (Lek, Ljubljana, Slovenia) at a concentration of 40 &#x003bc;g/mL. HUVEC cells, passage 5, were seeded at a density of 15 000 cells per well into 24-well cell culture plates in the modified EGM-2 medium (Lonza, Cat. No. CC-3156), supplemented with the SingleQuots<sup>&#x000ae;</sup> Kit (Lonza, Cat. No. CC-4176) without VEGF. The reason for the slightly higher seeding density of HUVEC cells was the lower proliferation activity of these cells in comparison with THP-1 cells, as was revealed in our preliminary experiments. Recombinant &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was added into both types of media at a concentration of 0 ng/mL, 20 ng/mL, and 50 ng/mL. The cells were cultured for 3 and 6 days, and then the media were collected for cytokine and chemokine analysis. The media without &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>, taken from THP-1 or HUVEC cells, were used as a negative control.</p><p>As a positive control, lipopolysaccharides from <italic>Escherichia coli</italic> 026:B6 (Sigma, Cat. No. L2654) were added into the cell culture media (i.e. RPMI or EGM-2) at concentrations of 10 ng/mL, 100 ng/mL, and 1000 ng/mL on day 2 and 5. The media were collected 24 hours later for cytokine and chemokine analysis [<xref rid="pone.0163697.ref047" ref-type="bibr">47</xref>]. The positive controls contained no &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>.</p><p>A Human Luminex Performance Assay Base Kit, Panel A (R&#x00026;D Systems, Cat. No. LUH000) was used to analyze IL-1&#x003b1;, IL-1&#x003b2;, GM-CSF, TNF-&#x003b1;, MCP-1 and IL-8. The array uses color-coded microparticles, which are pre-coated with specific antibodies against cytokines or chemokines. The microparticles, incubated with samples, bind the analytes of interest. After washing, a biotinylated antibody cocktail specific to the analytes of interest is added into each well. After washing and removing the unbound antibody, streptavidin-phycoerythrin conjugate is added into each well and binds the biotinylated antibody. Finally, one laser of the Luminex analyzer determines the magnitude of the phycoerythrin signal, and the other laser determines a microparticle-specific signal of the analyte bound.</p><p>The array was processed according to the manufacturer&#x02019;s protocol with some modifications (using Uniplate-Microplate Devices, 96-well, U Bottom, Whatman TM, instead of the original plate). Briefly, the samples were centrifuged at 200 g for 7 min. The microplate was pre-wetted with 100 &#x003bc;L of Wash Buffer, centrifuged at 900 g for 10 min. The microparticle concentrate was centrifuged at 1000 g for 30 sec, resuspended in the same solution and diluted according to the manufacturer&#x02019;s protocol. The diluted microparticles (50 &#x003bc;L) were added into each well, followed by 50 &#x003bc;L of standards and media samples. Covered by an aluminium foil, the plate was incubated for 3 hours at room temperature at 500 rpm, subsequently centrifuged at 900 g for 10 min and washed 3 times with 100 &#x003bc;L of Wash Buffer. Then 50 &#x003bc;L of diluted Biotin Antibody Cocktail was added to each well. Covered by an aluminium foil, the plate was incubated for 1 hour at room temperature at 500 rpm and then washed 3 times with 100 &#x003bc;L of Wash Buffer. Then 50 &#x003bc;L of diluted Streptavidin-Phycoerythrin solution was added to each well, incubated for l hour, and subsequently the wells were washed 3 times with 100 &#x003bc;L of Wash Buffer. The microparticles were then resuspended in 100 &#x003bc;L of Wash buffer and the cytokine concentrations were analyzed on Luminex LABScan 3D (Luminex, Netherlands) from 3 parallel samples. The cytokine concentrations were normalized per 100 000 cells, similarly as in our earlier study [<xref rid="pone.0163697.ref047" ref-type="bibr">47</xref>].</p></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><sec id="sec013"><title>Expression and purification of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub></title><p>The gene sequence encoding the modified variant of human VEGF<sub>121</sub> (&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>) was synthesized and subcloned between restriction sites <italic>Msc</italic> I and <italic>Xho</italic> I of the expression vector pET-32a(+) after the thioredoxin (Trx) gene and the hexahistidine tag. The resulting expression vector pET32-VEGF<sub>121</sub> was used to transform the <italic>E</italic>. <italic>coli</italic> Origami B (DE3) strain along with plasmid pGro7 encoding bacterial chaperones GroEL/GroES. The recombinant protein Trx&#x02013;&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was expressed as a fusion protein composed of thioredoxin, histidine tag, thrombin cleavage site, factor XIIIa substrate sequence NQEQVSPL derived from &#x003b1;<sub>2</sub>-plasmin inhibitor and VEGF<sub>121</sub> (<xref ref-type="fig" rid="pone.0163697.g001">Fig 1</xref>, <xref ref-type="supplementary-material" rid="pone.0163697.s012">S1 Text</xref>). A high level of recombinant protein expression was achieved after the induction of recombinant bacteria with 0.02 mM IPTG and subsequent culture growth at 25&#x000b0;C for 20&#x02013;22 h. The ratio of the soluble protein fraction and the insoluble protein fraction was determined by SDS-PAGE. An analysis with Gel Analyzer software (<ext-link ext-link-type="uri" xlink:href="http://www.gelanalyzer.com">http://www.gelanalyzer.com</ext-link>) showed that 43% of the Trx&#x02013;&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was expressed in soluble form (<xref ref-type="fig" rid="pone.0163697.g002">Fig 2</xref>, lanes 3 and 4). Trx&#x02013;&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was purified from the soluble fraction of cytoplasmic proteins using Talon Metal Affinity Resin (<xref ref-type="fig" rid="pone.0163697.g002">Fig 2</xref>, lane 6). After purification, the fusion partner was cleaved out with thrombin. The molecular mass of the Trx&#x02013;&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> fusion protein estimated by SDS-PAGE was 32.5 kDa (theoretical molecular mass 29.2 kDa). Cleavage of the fusion partner containing the hexahistidine tag with thrombin yielded a thioredoxin fragment (15.1 kDa, theoretical molecular mass 13.9 kDa) and &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> (18.8 kDa, theoretical molecular mass 15.3 kDa; <xref ref-type="fig" rid="pone.0163697.g002">Fig 2</xref>, line 7). The yield of purified &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> determined by the Bradford protein assay was 1.4 mg protein per 1 L of culture medium.</p><fig id="pone.0163697.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0163697.g001</object-id><label>Fig 1</label><caption><title>Amino acid sequence of expressed Trx&#x02013;&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> fusion protein.</title><p>His tag = hexahistidine tag; Thr = thrombin cleavage site; FXIIIa = Factor XIIIa substrate sequence NQEQVSPL; VEGF<sub>121</sub> = vascular endothelial growth factor A121; resulting recombinant protein &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> after cleavage of the fusion part shown in bold.</p></caption><graphic xlink:href="pone.0163697.g001"/></fig><fig id="pone.0163697.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0163697.g002</object-id><label>Fig 2</label><caption><title>Expression in <italic>E</italic>. <italic>coli</italic> Origami B (DE3), purification and removal of the thioredoxin fusion part (Trx) of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>.</title><p>Molecular weight markers (<bold>1</bold>), uninduced cells (<bold>2</bold>), cells induced with IPTG and L-arabinose, soluble fraction (<bold>3</bold>), cells induced with IPTG and L-arabinose, insoluble fraction (<bold>4</bold>), unbound proteins (<bold>5</bold>), purified fusion protein Trx-&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> (<bold>6</bold>), preparation of the fusion protein Trx-&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> after cleavage with thrombin (<bold>7</bold>), purified &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> (<bold>8</bold>).</p></caption><graphic xlink:href="pone.0163697.g002"/></fig></sec><sec id="sec014"><title>Mitogenic activity of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub></title><p>To test the mitogenic activity of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>, the proliferative effect on HUVEC cells was investigated using the xCELLigence system and a resazurin-based assay. The activity of recombinant &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was compared to the activity of VEGF<sub>121</sub> from commercial sources. For this purpose, we used a VEGF<sub>121</sub> variant expressed in <italic>E</italic>. <italic>coli</italic> and a variant expressed in mammalian HEK cells. Three concentrations of VEGF<sub>121</sub> (20, 50 and 100 ng/mL) were used for the evaluation. The concentrations of each VEGF<sub>121</sub> variant were determined by ELISA analysis. The EGM-2 cultivation medium without growth factors served as a negative control.</p><p>The evaluation showed that the recombinant &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> manufactured in this work had a greater impact on HUVEC proliferation than the two tested commercially-available VEGF<sub>121</sub> variants. This effect was most apparent at a concentration of 50 ng/mL of VEGF<sub>121</sub> (see <xref ref-type="fig" rid="pone.0163697.g003">Fig 3</xref>, <xref ref-type="supplementary-material" rid="pone.0163697.s004">S3 Fig</xref>), but it was also observed at VEGF<sub>121</sub> concentrations of 20 and 100 ng/mL (see <xref ref-type="supplementary-material" rid="pone.0163697.s002">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0163697.s008">S7</xref> Figs).</p><fig id="pone.0163697.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0163697.g003</object-id><label>Fig 3</label><caption><title>VEGF mitogenic activity evaluation using the xCELLigence system.</title><p>The mitogenic activity of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> and commercial VEGF<sub>121</sub> standards was evaluated using real-time monitoring of HUVEC cell proliferation. &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>, 50 ng/mL (<bold>1</bold>), VEGF<sub>121</sub>
<bold>I</bold>, 50 ng/mL (<bold>2</bold>), VEGF<sub>121</sub>
<bold>II</bold>, 50 ng/mL (<bold>3</bold>), negative control (culture medium without VEGF) (<bold>4</bold>). The cells were incubated for 165 hours. The results shown here are mean &#x000b1; SEM (n = 4).</p></caption><graphic xlink:href="pone.0163697.g003"/></fig><p>The plateau value of the cell index (evaluated at 165 hours, i.e. on day 7) for &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was 4.30 &#x000b1; 0.20; for VEGF<sub>121</sub>
<bold>I</bold> it was 1.11 &#x000b1; 0.11; for VEGF<sub>121</sub>
<bold>II</bold> it was 0.72 &#x000b1; 0.10, and for the culture medium without VEGF<sub>121</sub> the value was 0.43 &#x000b1; 0.06 (<xref ref-type="fig" rid="pone.0163697.g003">Fig 3</xref>). In other words, PI<sub>1-8</sub>-VEGF<sub>121</sub> expressed and purified under the described conditions showed an approximately 3.9 times greater effect on endothelial growth in comparison with the mitogenic activity of the VEGF<sub>121</sub>
<bold>I</bold> standard, and an approximately 6.0 times greater effect when compared to the mitogenic activity of VEGF<sub>121</sub>
<bold>II</bold> (<xref ref-type="fig" rid="pone.0163697.g003">Fig 3</xref>).</p><p>The data obtained in the xCELLigence system were further supported by an independent proliferation assay based on the fluorescent indicator resazurin, performed on the 2<sup>nd</sup>, 4<sup>th</sup> and 7<sup>th</sup> day of cultivation. Major differences were observed after 165 hours (day 7) of incubation in a cultivation medium containing 50 ng/mL of VEGF<sub>121</sub> preparations, where the relative cell counts were 11.5 &#x000b1; 0.6% for VEGF<sub>121</sub>
<bold>I</bold> and 13.3 &#x000b1; 2.7% for VEGF121 <bold>II</bold>, in comparison with recombinant &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> (100%, <xref ref-type="fig" rid="pone.0163697.g004">Fig 4</xref>). This effect was also observed at VEGF<sub>121</sub> concentrations of 20 and 100 ng/mL (see <xref ref-type="supplementary-material" rid="pone.0163697.s003">S2</xref> and <xref ref-type="supplementary-material" rid="pone.0163697.s005">S4</xref> Figs). Thus, &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> increased endothelial proliferation 8.7 times in comparison with VEGF<sub>121</sub>
<bold>I</bold> and 7.5 times in comparison with VEGF<sub>121</sub>
<bold>II</bold> (<xref ref-type="fig" rid="pone.0163697.g004">Fig 4</xref>).</p><fig id="pone.0163697.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0163697.g004</object-id><label>Fig 4</label><caption><title>The comparison of endothelial cell proliferation in media containing VEGF<sub>121</sub> (50 ng/ mL) from different sources.</title><p>Relative cell count in a cultivation medium containing the examined VEGF<sub>121</sub> preparations (&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> from this work, VEGF<sub>121</sub>
<bold>I</bold> expressed in <italic>E</italic>. <italic>coli</italic>, and VEGF<sub>121</sub>
<bold>II</bold> expressed in HEK cells) assessed with the fluorescent indicator resazurin after 48 hours (day 2), 96 hours (day 4), and 165 hours (day 7) of incubation, compared to the control with no VEGF (= 0%). The VEGF concentration in all preparations was 50 ng/mL. Results shown as mean &#x000b1; SEM (n = 4). The statistical significance was determined by the ANOVA, Student&#x02013;Newman&#x02013;Keuls method; p&#x0003c;0.05 in comparison with the samples indicated by numbers (in blue) above the columns.</p></caption><graphic xlink:href="pone.0163697.g004"/></fig></sec><sec id="sec015"><title>Effect of thrombin on HUVEC proliferation</title><p>As revealed by the real-time monitoring of cell growth using the xCELLigence system, the addition of thrombin in concentrations of 0.01, 0.05, 0.1 and 1.0 NIH U/mL to the media with VEGF<sub>121</sub> standards (concentrations of 20, 50 and 100 ng/mL) did not significantly change the proliferation activity of HUVEC cells. The growth dynamics of HUVEC in the presence of the thrombin + VEGF<sub>121</sub> standards were similar as in the presence of the VEGF<sub>121</sub> standards only (<xref ref-type="fig" rid="pone.0163697.g005">Fig 5</xref>, <xref ref-type="supplementary-material" rid="pone.0163697.s006">S5 Fig</xref>).</p><fig id="pone.0163697.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0163697.g005</object-id><label>Fig 5</label><caption><title>The effect of thrombin (0.01, 0.05, 0.1 and 1.0 NIH U/mL) on the proliferation of HUVEC cells.</title><p>Seeding density 3 500 cells per well of a 96-well E-plate in EBM-2 basal medium supplemented with ascorbic acid, hydrocortisone, heparin, gentamicin, amphotericin-B and 2% fetal bovine serum from EGM-2 SingleQuots and in the presence of the commercial VEGF<sub>121</sub>
<bold>I</bold> standard (50 ng/mL) or &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> followed by the xCELLigence system.</p></caption><graphic xlink:href="pone.0163697.g005"/></fig><p>Curves: &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> (<bold>1</bold>), control VEGF<sub>121</sub>
<bold>I</bold> (<bold>2</bold>), control VEGF<sub>121</sub>
<bold>I</bold> + thrombin 0.01 NIH U/mL (<bold>3</bold>), control VEGF<sub>121</sub>
<bold>I</bold> + thrombin 0.05 NIH U/mL (<bold>4</bold>), control VEGF<sub>121</sub>
<bold>I</bold> + thrombin 0.10 NIH U/mL (<bold>5</bold>), control VEGF<sub>121</sub>
<bold>I</bold> + thrombin 1.00 NIH U/mL (<bold>6</bold>), negative control: no VEGF<sub>121</sub> + no thrombin (<bold>7</bold>).</p><p>The mitogenic activity of the preparations (controls) was evaluated using real-time monitoring of HUVEC cell proliferation. The cells were monitored every 15 minutes for 163 hours. The results shown here are mean &#x000b1; SEM (n = 4). VEGF<sub>121</sub>
<bold>I</bold> expressed in <italic>E</italic>. <italic>coli</italic> (50 ng/mL) was used as a standard.</p></sec><sec id="sec016"><title>Cell immune activation by VEGF<sub>121</sub></title><p>The Luminex Performance Assay revealed that THP-1 monocyte-like cells, cultured with &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> (in a concentration of 0, 20 or 50 ng/mL), did not produce Il-1&#x003b1;, Il-1&#x000df; and GM-CSF cytokines in a concentration detectable in the cell culture media. However, when the THP-1 cells were stimulated with bacterial lipopolysaccharide (LPS, concentrations from 10 to 1000 ng/mL), i.e. an endotoxin often used as a positive control in studies of cell immune activation, these cells produced Il-1&#x003b1;, Il-1&#x000df;, and GM-CSF in high concentrations (<xref ref-type="fig" rid="pone.0163697.g006">Fig 6A&#x02013;6C</xref>, <xref ref-type="supplementary-material" rid="pone.0163697.s007">S6 Fig</xref>). However, &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> stimulated the THP-1 cells to produce TNF-&#x003b1;, MCP-1 and IL-8. The production of these molecules was proportional to the &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> concentration, but it was rather transient and was apparent in considerable amounts only for 3 days. After 6 days of culture, the concentration of TNF-&#x003b1;, MCP-1 and IL-8 in the cell culture media dropped to very low values (<xref ref-type="fig" rid="pone.0163697.g006">Fig 6D&#x02013;6F</xref>, <xref ref-type="supplementary-material" rid="pone.0163697.s007">S6 Fig</xref>). However, LPS massively stimulated the production of TNF-&#x003b1;, MCP-1 and IL-8 by THP-1 cells at both time intervals, so their concentrations in the media exceeded the standard calibration curve of the array, even at the lowest LPS concentration of 10 ng/mL. As for the HUVEC cells, &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> stimulated the production of GM-CSF, but this production was markedly lower that the values obtained after stimulation with LPS, even in the lowest concentration (<xref ref-type="fig" rid="pone.0163697.g006">Fig 6G</xref>, <xref ref-type="supplementary-material" rid="pone.0163697.s007">S6 Fig</xref>). Thus, the potential of our recombinant VEGF<sub>121</sub> to induce cell immune activation and an inflammatory reaction can be qualified as relatively low.</p><fig id="pone.0163697.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0163697.g006</object-id><label>Fig 6</label><caption><title>Cell immune activation by VEGF<sub>121</sub> determined by Luminex Performance Assay.</title><p>Concentration of IL-1&#x003b1; (A), IL-1&#x000df; (B), GM-CSF(C, G), TNF-&#x003b1; (D), MCP-1 (E) and IL-8 (F) produced by THP-1 cells (A-F) or HUVEC (G) in the cell culture medium on day 3 (D3) or day 6 (D6) of cultivation in media with 0, 20 and 50 ng/mL of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> (VEGF) or 10, 100 or 1000 ng/mL of bacterial lipopolysaccharide (LPS). The cells were seeded into 24-well culture plates in 1.5 ml of the media (THP-1: 10 000 cells/well, RPMI-1640 medium; HUVEC: 15 000 cells/well, EGM-2 medium without commercial VEGF<sub>121</sub> supplement). The amount of cytokines or chemokines in the media was calculated per 10<sup>5</sup> cells. Mean &#x000b1; S.E.M. (standard error of mean) from 3 measurements for each experimental group and time interval. The mean value is shown in italics (in red) above the columns. Values higher than the calibration curve are indicated with &#x0201c;&#x0003e;&#x0201d;. The statistical significance was determined by the ANOVA, Student&#x02013;Newman&#x02013;Keuls method; p&#x0003c;0.05 in comparison with the samples indicated by numbers (in blue) above the columns.</p></caption><graphic xlink:href="pone.0163697.g006"/></fig></sec></sec><sec sec-type="conclusions" id="sec017"><title>Discussion</title><p>Most studies on VEGF expression in bacteria describe its purification from insoluble inclusion bodies by the denaturing and refolding method, where the recovery of protein biological activity may be a problem [<xref rid="pone.0163697.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0163697.ref048" ref-type="bibr">48</xref>&#x02013;<xref rid="pone.0163697.ref053" ref-type="bibr">53</xref>]. However, only a small number of studies have shown the heterologous expression of VEGF in <italic>E</italic>. <italic>coli</italic> in the soluble protein fraction [<xref rid="pone.0163697.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0163697.ref054" ref-type="bibr">54</xref>]. Our work is one of the rare cases in which VEGF is expressed in <italic>E</italic>. <italic>coli</italic> in a soluble form.</p><p>VEGF belongs to the cystine knot superfamily of growth factors. The cystine knot consists of nine cysteine residues that are present within the VEGF<sub>121</sub> structure and play a role in protein dimerization. Due to the absence of a hydrophobic core region, the cystine knot is believed to be the major determinant of protein stability [<xref rid="pone.0163697.ref055" ref-type="bibr">55</xref>]. This complex structure may be responsible for the higher requirements on protein folding quality when expressed heterologously. In accordance with studies that have also dealt with the expression of proteins with a similar structure [<xref rid="pone.0163697.ref038" ref-type="bibr">38</xref>&#x02013;<xref rid="pone.0163697.ref040" ref-type="bibr">40</xref>], pET-32a(+) vector and <italic>E</italic>. <italic>coli</italic> Origami B (DE3) host cells were chosen for &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> production. Moreover, to ameliorate protein folding, &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was co-expressed with GroEL/ES chaperones, which have been reported to increase the solubility, the yield, and in some cases even the biological activity of several recombinant proteins [<xref rid="pone.0163697.ref056" ref-type="bibr">56</xref>&#x02013;<xref rid="pone.0163697.ref062" ref-type="bibr">62</xref>]. To the best of our knowledge, co-expression of VEGF protein with molecular chaperones has not been published before.</p><p>About 43% of recombinant thioredoxin-&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> fusion protein was expressed in the soluble protein fraction. The corresponding molecular mass was found to be 32.5 kDa (<xref ref-type="fig" rid="pone.0163697.g002">Fig 2</xref>), which was in a good agreement with the expected theoretical size of the fusion protein (29.2 kDa). Two other dominant protein bands present in the soluble protein fraction on an SDS-PAGE gel correspond to a molecular mass of ca 58 and 16 kDa (<xref ref-type="fig" rid="pone.0163697.g002">Fig 2</xref>, column l and 3). These protein bands were interpreted as molecular chaperones GroEL and GroES. The putative GroEL protein was present in both the soluble protein fraction and the insoluble protein fraction (<xref ref-type="fig" rid="pone.0163697.g002">Fig 2</xref>, lanes 3, 4). The apparent presence in a fraction of unbound proteins suggests a weak interaction with Talon Metal Affinity Resin, which was used for affinity chromatography (<xref ref-type="fig" rid="pone.0163697.g002">Fig 2</xref>, lane 5).</p><p>During dialysis following affinity chromatography, an unspecified amount of the protein precipitated. Thus, although the expression of the soluble protein fraction was high (<xref ref-type="fig" rid="pone.0163697.g002">Fig 2</xref>), the overall yield of 1.4 mg per L of culture was lower than expected. The yield of recombinantly prepared VEGF mentioned in related studies varies on a case-by-case basis. Some studies do not present any yield [<xref rid="pone.0163697.ref049" ref-type="bibr">49</xref>, <xref rid="pone.0163697.ref054" ref-type="bibr">54</xref>] or the data are unclear [<xref rid="pone.0163697.ref038" ref-type="bibr">38</xref>]. In other works, the yield of purified active VEGF<sub>121</sub> or VEGF<sub>165</sub> is between 1 mg and 5 mg per L of bacterial culture [<xref rid="pone.0163697.ref050" ref-type="bibr">50</xref>, <xref rid="pone.0163697.ref052" ref-type="bibr">52</xref>, <xref rid="pone.0163697.ref053" ref-type="bibr">53</xref>], which is similar to the yield of mutant VEGF<sub>121</sub> purified in this work. The yield of recombinantly expressed &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> by Zisch et al. was 11 mg/L [<xref rid="pone.0163697.ref030" ref-type="bibr">30</xref>].</p><p>The SDS-PAGE record of purified &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> did not show any contamination, but it is possible that small traces of thrombin used for cleavage of the thioredoxin fusion part remained in the solution. It has been reported that a low concentration of thrombin is able to stimulate the proliferation of endothelial cells. In earlier studies, the addition of thrombin to HUVEC cells cultivated in serum-free conditions resulted in significant dose- and time-dependent stimulation of endothelial cell proliferation, with a maximal effect at concentrations of thrombin of ca 0.04&#x02013;0.08 NIH U/mL [<xref rid="pone.0163697.ref041" ref-type="bibr">41</xref>&#x02013;<xref rid="pone.0163697.ref043" ref-type="bibr">43</xref>]. However, in our study, similar or even higher concentrations of thrombin (0.01, 0.05, 0.1 and 1.0 NIH U/mL) had no significant influence on the HUVEC proliferation (<xref ref-type="fig" rid="pone.0163697.g005">Fig 5</xref>). A positive effect of thrombin on the very high mitogenic activity of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> can therefore be excluded.</p><p>After cleavage of the thioredoxin fusion part by thrombin, the mitogenic activity of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> was evaluated by two independent methods, namely by real-time monitoring of endothelial cell proliferation by the xCELLigence system, and by the fluorescent indicator resazurin. Both assays revealed that &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> expressed and purified under the conditions described here showed a significantly greater effect on endothelial cell growth than the mitogenic activity of the VEGF<sub>121</sub>
<bold>I</bold> and <bold>II</bold> standards. This effect was the most apparent after 7 days, when, at a concentration of 50 ng/mL, &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> increased the endothelial cell proliferation approximately 3.9 to 8.7 times more than the VEGF<sub>121</sub>
<bold>I</bold> and II (Figs <xref ref-type="fig" rid="pone.0163697.g003">3</xref> and <xref ref-type="fig" rid="pone.0163697.g004">4</xref>). The concentrations of all VEGF<sub>121</sub> preparations used in this work were determined by VEGF-ELISA, under the same experimental conditions (see <xref ref-type="supplementary-material" rid="pone.0163697.s009">S1 Table</xref>). This suggests that the relative VEGF<sub>121</sub> activity was not influenced by incorrect determination of the VEGF<sub>121</sub> concentration. The highly mitogenic &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> created in this study (even with a relatively low yield) could be used effectively for improving of endothelialization of various biomaterials, where it could be incorporated in lower concentrations than those usually applied. This option would be helpful for reducing undesirable side-effects of VEGF, such as inflammation, induced by overexpression of VEGF [<xref rid="pone.0163697.ref045" ref-type="bibr">45</xref>].</p><p>Recombinant &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> contains an additional N-terminal substrate sequence (NQEQVSPL) for factor XIIIa, but there is no evidence that such a short peptide should influence the biological activity of VEGF<sub>121</sub>. Studies comparing the biological activities of various VEGF preparations have not found any significant differences [<xref rid="pone.0163697.ref053" ref-type="bibr">53</xref>, <xref rid="pone.0163697.ref063" ref-type="bibr">63</xref>]. The biological activity was also comparable to that of the commercial standard in the case of VEGF proteins joined to uncleaved fusion partners, such as thioredoxin or GST [<xref rid="pone.0163697.ref049" ref-type="bibr">49</xref>, <xref rid="pone.0163697.ref050" ref-type="bibr">50</xref>].</p><p>Work evaluating the biological activity of recombinant VEGF with an uncleaved C-terminal GST fusion partner shows that the presence of GST did not affect the correct assembly of dimers and the display of residues critical for receptor recognition [<xref rid="pone.0163697.ref050" ref-type="bibr">50</xref>]. A similar finding was reported in a study describing the functionality of VEGF<sub>165</sub> N-terminally fused to thioredoxin, where the authors found that N-terminal extension decreased the affinity of VEGF fusion proteins to VEGFR-2, but at saturated concentrations these proteins were as efficient as VEGF<sub>165</sub> of the correct size [<xref rid="pone.0163697.ref049" ref-type="bibr">49</xref>]. Unlike the activity of our &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>, which was 8.7 times higher than the activity of the VEGF<sub>121</sub>
<bold>I</bold> standard, the activity of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> prepared without chaperones [<xref rid="pone.0163697.ref030" ref-type="bibr">30</xref>] was only comparable with the activity of unmodified, <italic>E</italic>. <italic>coli</italic>-derived VEGF<sub>121</sub>. However, in many papers there is no comparison of biological activity with a commercial VEGF standard [<xref rid="pone.0163697.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0163697.ref048" ref-type="bibr">48</xref>, <xref rid="pone.0163697.ref051" ref-type="bibr">51</xref>, <xref rid="pone.0163697.ref052" ref-type="bibr">52</xref>, <xref rid="pone.0163697.ref054" ref-type="bibr">54</xref>].</p><p>It has been shown that administering the thioredoxin gene can stimulate the proliferation of mesenchymal stem cells [<xref rid="pone.0163697.ref064" ref-type="bibr">64</xref>]. When thioredoxin is added into the media in the form of a protein, concentrations as high as 5&#x02013;70 &#x003bc;g/mL were observed to have an impact on the cell growth [<xref rid="pone.0163697.ref065" ref-type="bibr">65</xref>]. Regarding the level of efficient thioredoxin concentration, the high mitogenic activity of the manufactured VEGF observed in our experiments should not be related to the traces of hypothetical thioredoxin contamination, which were far below 50 ng/mL. The his-tagged <italic>E</italic>. <italic>coli</italic> thioredoxin, which was used in this work as a fusion partner, was cleaved out and removed by affinity chromatography. Its elimination was confirmed by SDS-PAGE analysis of the final VEGF<sub>121</sub> preparation. In addition, as mentioned above, the biological activity of recombinant VEGF was not increased even if its fusion partner, thioredoxin, was not cleaved out [<xref rid="pone.0163697.ref049" ref-type="bibr">49</xref>, <xref rid="pone.0163697.ref050" ref-type="bibr">50</xref>].</p><p>Thus, a positive role of thrombin, NQEQVSPL or thioredoxin in the increased mitogenic activity of our recombinant &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> can be ruled out. However, it should be noted that the commercial VEGF<sub>121</sub> standards that were available to us (i.e., purchased from Prospecbio, Cat. No. CYT-343 and CYT-116) were obtained in the form of a lyophilized powder recommended to be reconstituted in PBS. Proteins in general may lose their biological activity during lyophilization or reconstitution. Presumably, all this could reduce the biological activity of the VEGF<sub>121</sub> standards.</p><p>The high mitogenic activity &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> created in this study may be caused by co-expression of the growth factor with molecular chaperones that have not been used so far in VEGF production. A similar phenomenon was observed in the case of several recombinant proteins expressed in <italic>E</italic>. <italic>coli</italic>. For example, the relative binding activity of anti-B-type natriuretic peptide scFv [<xref rid="pone.0163697.ref057" ref-type="bibr">57</xref>], and the specific enzyme activities of nitrilase [<xref rid="pone.0163697.ref056" ref-type="bibr">56</xref>], and also cold-active lipase Lip-948 [<xref rid="pone.0163697.ref066" ref-type="bibr">66</xref>], were increased by co-expression with molecular chaperones. In the case of VEGF, chaperones could either stabilize an optimal folding structure during the expression, or could selectively solubilize a highly active VEGF fraction. However, this interesting but complicated issue needs further investigation.</p><p>Our analysis of cell immune activation suggested that the potential of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> to induce the production of inflammatory cytokines and chemokines in cells and their release into the cell culture media is relatively low. This conclusion is based on our findings that upon stimulation by &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>, human monocyte-like THP-1 cells did not release measurable quantities of IL-1&#x003b1;, IL-1&#x003b2; and GM-CSF, and released only small amounts of IL-8, TNF- &#x003b1; and MCP-1 in comparison to cells stimulated by LPS. HUVEC cells were able to release only GM-CSF, but its concentration was again very low compared with the values obtained after LPS stimulation. These results can be considered as favorable for our intended future use of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> for incorporation into fibrin matrices for potential modification of cardiovascular implants and scaffolds for tissue engineering in order to improve their endothelialization or vascularization. However, in other studies, both recombinant and natural VEFG molecules have been reported to act as pro-inflammatory factors, which activated cells of the immune system (leucocytes, lymphocytes, monocytes and macrophages), and also vascular endothelial cells to produce pro-inflammatory cytokines, chemokines, and adhesion molecules of immunoglobulin and selectin families [<xref rid="pone.0163697.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0163697.ref045" ref-type="bibr">45</xref>]. In addition, recombinant VEGF molecules are capable of inducing the production of antibodies when administered into organisms <italic>in vivo</italic>. This has been used for producing vaccines against tumors [<xref rid="pone.0163697.ref067" ref-type="bibr">67</xref>, <xref rid="pone.0163697.ref068" ref-type="bibr">68</xref>]. A vaccine based on human recombinant VEGF combined with a bacterial adjuvant has even been tested in a phase I clinical trial on patients with advanced solid tumors [<xref rid="pone.0163697.ref069" ref-type="bibr">69</xref>].</p></sec><sec sec-type="conclusions" id="sec018"><title>Conclusion</title><p>In this work we have described a new procedure by which a highly active mutant variant &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> can be produced. The mutant protein structure was first designed by Zisch et al. [<xref rid="pone.0163697.ref030" ref-type="bibr">30</xref>], and was used for preparing fibrin gels with incorporated VEGF<sub>121</sub>. The new procedure, based on co-expressing thioredoxin-&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> with recombinant molecular chaperones GroES/EL, resulted in mitogenic activity of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> that was 3.9&#x02013;8.7 times higher than the mitogenic activity of commercial VEGF<sub>121</sub> standards. Very high mitogenic activity and a low effect on inducing the inflammatory activation of human endothelial HUVEC cells and human monocyte-like THP-1 cells make this &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> variant attractive for fibrin-based biomaterials releasing VEGF<sub>121</sub>, e.g. for coating cardiovascular implants in order to improve their endothelialization.</p></sec><sec sec-type="supplementary-material" id="sec019"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0163697.s001"><label>S1 Dataset</label><caption><title>SDS-PAGE outputs of expression in <italic>E</italic>. <italic>coli</italic> Origami B (DE3), purification and removal of the thioredoxin fusion part (Trx) of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>.</title><p>(DOCX)</p></caption><media xlink:href="pone.0163697.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s002"><label>S1 Fig</label><caption><title>Mitogenic activity of VEGF<sub>121</sub> (20, 50 and 100 ng/mL) evaluated using the xCELLigence system.</title><p>The mitogenic activity of the &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> and commercial VEGF<sub>121</sub> standards was evaluated using real-time monitoring of HUVEC cell proliferation. Curves: &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>, 20, 50 and 100 ng/mL (<bold>3, 2, 1</bold>), VEGF<sub>121</sub>
<bold>I</bold>, 20, 50 and 100 ng/mL (<bold>5, 4, 6</bold>), VEGF<sub>121</sub>
<bold>II</bold>, 20, 50 and 100 ng/mL (<bold>9, 8, 7</bold>), negative control (culture medium without VEGF) (<bold>10</bold>). The cells were incubated for 165 hours. The results shown here are mean &#x000b1; SEM (n = 4).</p><p>(TIF)</p></caption><media xlink:href="pone.0163697.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s003"><label>S2 Fig</label><caption><title>The comparison of endothelial cell proliferation in media containing VEGF<sub>121</sub> (20 and 100 ng/ mL) from different sources.</title><p>Relative cell count in a cultivation medium containing the examined VEGF<sub>121</sub> preparations (&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> from this work, VEGF<sub>121</sub>
<bold>I</bold> expressed in <italic>E</italic>. <italic>coli</italic>, and VEGF<sub>121</sub>
<bold>II</bold> expressed in HEK cells) assessed with the fluorescent indicator resazurin after 48 hours (day 2), 96 hours (day 4) and 165 hours (day 7) of incubation, compared to the control with no VEGF (= 0%). The VEGF<sub>121</sub> concentration in all preparations was 20 ng/mL (A) and 100 ng/mL (B). Results shown as mean &#x000b1; SEM (n = 4). The statistical significance was determined by the ANOVA, Student&#x02013;Newman&#x02013;Keuls method; p&#x0003c;0.05 in comparison with the samples indicated by numbers (in blue) above the columns.</p><p>(TIF)</p></caption><media xlink:href="pone.0163697.s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s004"><label>S3 Fig</label><caption><title>xCELLigence system output (VEGF mitogenic activity evaluation).</title><p>The mitogenic activity of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> and commercial VEGF<sub>121</sub> standards evaluated using real-time monitoring of HUVEC cell proliferation. &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>, 50 ng/mL (<bold>1</bold>), VEGF<sub>121</sub>
<bold>I</bold>, 50 ng/mL (<bold>2</bold>), VEGF<sub>121</sub>
<bold>II</bold>, 50 ng/mL (<bold>3</bold>), negative control (culture medium without VEGF) (<bold>4</bold>). Excel sheet of raw data (mean &#x000b1; standard error of the mean (S.E.M.)).</p><p>(XLSX)</p></caption><media xlink:href="pone.0163697.s004.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s005"><label>S4 Fig</label><caption><title>Microplate reader fluorescence measurement output (proliferation assay based on the fluorescent indicator resazurin for VEGF concentration 20, 50 and 100 ng/mL).</title><p>Relative cell count in a cultivation medium containing the examined VEGF<sub>121</sub> preparations (&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> from this work, VEGF<sub>121</sub>
<bold>I</bold> expressed in <italic>E</italic>. <italic>coli</italic>, and VEGF<sub>121</sub>
<bold>II</bold> expressed in HEK cells) assessed with the fluorescent indicator resazurin after 48 hours (day 2), 96 hours (day 4), and 165 hours (day 7) of incubation, compared to the control with no VEGF (= 0%). The VEGF concentration in preparations was 20, 50 and 100 ng/mL. Excel sheet of raw data (mean &#x000b1; S.E.M.).</p><p>(XLSX)</p></caption><media xlink:href="pone.0163697.s005.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s006"><label>S5 Fig</label><caption><title>xCELLigence system output (the effect of thrombin (0.01, 0.05, 0.1 and 1.0 NIH U/mL) on the proliferation of HUVEC cells).</title><p>&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> (<bold>1</bold>), control VEGF<sub>121</sub>
<bold>I</bold> (<bold>2</bold>), control VEGF<sub>121</sub>
<bold>I</bold> + thrombin 0.01 NIH U/mL (<bold>3</bold>), control VEGF<sub>121</sub>
<bold>I</bold> + thrombin 0.05 NIH U/mL (<bold>4</bold>), control VEGF<sub>121</sub>
<bold>I</bold> + thrombin 0.10 NIH U/mL (<bold>5</bold>), control VEGF<sub>121</sub>
<bold>I</bold> + thrombin 1.00 NIH U/mL (<bold>6</bold>), negative control: no VEGF + no thrombin (<bold>7</bold>). Excel sheet of raw data (mean &#x000b1; S.E.M.).</p><p>(XLSX)</p></caption><media xlink:href="pone.0163697.s006.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s007"><label>S6 Fig</label><caption><title>Cell immune activation by VEGF determined by Luminex Performance Assay.</title><p>Concentration of IL-1&#x003b1; (A), IL-1&#x000df; (B), GM-CSF(C, G), TNF-&#x003b1; (D), MCP-1 (E) and IL-8 (F) produced by THP-1 cells (A-F) or HUVEC (G) in the cell culture medium on day 3 (D3) or day 6 (D6) of cultivation in media with 0, 20 and 50 ng/mL of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> (VEGF) or 10, 100 or 1000 ng/mL of bacterial lipopolysaccharide (LPS). Excel sheet of raw data from 3 measurements.</p><p>(XLSX)</p></caption><media xlink:href="pone.0163697.s007.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s008"><label>S7 Fig</label><caption><title>xCELLigence system output (VEGF mitogenic activity evaluation; VEGF 20, 50 and 100 ng/mL).</title><p>&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub>, 20, 50 and 100 ng/mL (<bold>3, 2, 1</bold>), VEGF<sub>121</sub>
<bold>I</bold>, 20, 50 and 100 ng/mL (<bold>5, 4, 6</bold>), VEGF<sub>121</sub>
<bold>II</bold>, 20, 50 and 100 ng/mL (<bold>9, 8, 7</bold>), negative control (culture medium without VEGF) (<bold>10</bold>). Excel sheet of raw data (mean &#x000b1; S.E.M.).</p><p>(XLSX)</p></caption><media xlink:href="pone.0163697.s008.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s009"><label>S1 Table</label><caption><title>VEGF concentration determination.</title><p>Due to the risk of underestimating the potential VEGF<sub>121</sub> concentration, we determined the VEGF<sub>121</sub> protein concentration independently. The VEGF<sub>121</sub> solutions were analyzed simultaneously by the FluoroProfile Protein quantification Kit and by VEGF-ELISA, in order to confirm whether VEGF-ELISA can detect VEGF in different solutions with same sensitivity. Our results suggest that VEGF-ELISA detected the VEGF in all VEGF solutions with similar sensitivity, and provided results that are 1.07&#x02013;1.70 times higher than those determined by FluoroProfile Protein quantification Kit.</p><p>(DOCX)</p></caption><media xlink:href="pone.0163697.s009.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s010"><label>S2 Table</label><caption><title>VEGF concentration determination using FluoroProfile Protein Quantification Kit (Cat. No. FP0010, Sigma-Aldrich) for protein concentration determination.</title><p>Excel sheet of raw data.</p><p>(XLSX)</p></caption><media xlink:href="pone.0163697.s010.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s011"><label>S3 Table</label><caption><title>VEGF concentration determination VEGF121-ELISA Kit (Cat. No. KHG0112, Invitrogen).</title><p>Excel sheet of raw data.</p><p>(XLSX)</p></caption><media xlink:href="pone.0163697.s011.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0163697.s012"><label>S1 Text</label><caption><title>Nucleotide sequence of &#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> gene and amino acid sequence of expressed Trx&#x02013;&#x003b1;<sub>2</sub>-PI<sub>1-8</sub>-VEGF<sub>121</sub> fusion protein.</title><p>(DOC)</p></caption><media xlink:href="pone.0163697.s012.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>This work has been supported by the Ministry of Education, Youth and Sports of the Czech Republic (Grant No. EE2.30.0029 and by National Sustainability Program II Project BIOCEV-FAR LQ1604), by the BIOCEV project (CZ.1.05/1.1.00/02.0109), by the Agency for the Czech Republic Health Research, Ministry of Health of the Czech Republic (Grant No. 15-29153A), and by the Technology Agency of the Czech Republic (grant No. TA04011345). Mr. Robin Healey (Czech Technical University in Prague, Czech Republic) is gratefully acknowledged for his language revision of the manuscript.</p></ack><ref-list><title>References</title><ref id="pone.0163697.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>P</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Yan</surname><given-names>Y</given-names></name>, <name><surname>Hu</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>W</given-names></name>, <name><surname>Cai</surname><given-names>K</given-names></name>. <article-title>Construction of extracellular microenvironment to improve surface endothelialization of NiTi alloy substrate</article-title>. <source>Mater Sci Eng C Mater Biol Appl</source>. <year>2015</year>; <volume>55</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>. Epub 2015 May 21. ; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.msec.2015.05.047">10.1016/j.msec.2015.05.047</ext-link></comment><pub-id pub-id-type="pmid">26117732</pub-id></mixed-citation></ref><ref id="pone.0163697.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>An</surname><given-names>Q</given-names></name>, <name><surname>Li</surname><given-names>D</given-names></name>, <name><surname>Wu</surname><given-names>T</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Sun</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Heparin and vascular endothelial growth factor loaded poly(L-lactide-co-caprolactone) nanofiber covered stent-graft for aneurysm treatment</article-title>. <source>J Biomed Nanotechnol</source>. <year>2015</year>;<volume>11</volume>(<issue>11</issue>):<fpage>1947</fpage>&#x02013;<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1166/jbn.2015.2138">10.1166/jbn.2015.2138</ext-link></comment> .<pub-id pub-id-type="pmid">26554154</pub-id></mixed-citation></ref><ref id="pone.0163697.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>JH</given-names></name>, <name><surname>Kim</surname><given-names>TH</given-names></name>, <name><surname>Jin</surname><given-names>GZ</given-names></name>, <name><surname>Park</surname><given-names>JH</given-names></name>, <name><surname>Yun</surname><given-names>YR</given-names></name>, <name><surname>Jang</surname><given-names>JH</given-names></name>, <etal>et al</etal>
<article-title>Mineralized poly(lactic acid) scaffolds loading vascular endothelial growth factor and the in vivo performance in rat subcutaneous model</article-title>. <source>J Biomed Mater Res A</source>. <year>2013</year>;<volume>101</volume>(<issue>5</issue>):<fpage>1447</fpage>&#x02013;<lpage>55</lpage>. Epub 2012 Oct 31. , <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jbm.a.34446">10.1002/jbm.a.34446</ext-link></comment><pub-id pub-id-type="pmid">23114998</pub-id></mixed-citation></ref><ref id="pone.0163697.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Maglione</surname><given-names>D</given-names></name>, <name><surname>Guerriero</surname><given-names>V</given-names></name>, <name><surname>Viglietto</surname><given-names>G</given-names></name>, <name><surname>Delli-Bovi</surname><given-names>P</given-names></name>, <name><surname>Persico</surname><given-names>MG</given-names></name>. <article-title>Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1991</year>; <volume>88</volume>(<issue>20</issue>):<fpage>9267</fpage>&#x02013;<lpage>71</lpage>. Epub 1991/10/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.88.20.9267">10.1073/pnas.88.20.9267</ext-link></comment> ; PubMed Central PMCID: PMCPmc52695.<pub-id pub-id-type="pmid">1924389</pub-id></mixed-citation></ref><ref id="pone.0163697.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Olofsson</surname><given-names>B</given-names></name>, <name><surname>Pajusola</surname><given-names>K</given-names></name>, <name><surname>Kaipainen</surname><given-names>A</given-names></name>, <name><surname>von Euler</surname><given-names>G</given-names></name>, <name><surname>Joukov</surname><given-names>V</given-names></name>, <name><surname>Saksela</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Vascular endothelial growth factor B, a novel growth factor for endothelial cells</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1996</year>; <volume>93</volume>(<issue>6</issue>):<fpage>2576</fpage>&#x02013;<lpage>81</lpage>. Epub 1996/03/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.93.6.2576">10.1073/pnas.93.6.2576</ext-link></comment> ; PubMed Central PMCID: PMCPmc39839.<pub-id pub-id-type="pmid">8637916</pub-id></mixed-citation></ref><ref id="pone.0163697.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Joukov</surname><given-names>V</given-names></name>, <name><surname>Pajusola</surname><given-names>K</given-names></name>, <name><surname>Kaipainen</surname><given-names>A</given-names></name>, <name><surname>Chilov</surname><given-names>D</given-names></name>, <name><surname>Lahtinen</surname><given-names>I</given-names></name>, <name><surname>Kukk</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases</article-title>. <source>The EMBO Journal</source>. <year>1996</year>; <volume>15</volume>(<issue>2</issue>):<fpage>290</fpage>&#x02013;<lpage>98</lpage>. Epub 1996/01/15. ; PubMed Central PMCID: PMCPmc449944.<pub-id pub-id-type="pmid">8617204</pub-id></mixed-citation></ref><ref id="pone.0163697.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Achen</surname><given-names>MG</given-names></name>, <name><surname>Jeltsch</surname><given-names>M</given-names></name>, <name><surname>Kukk</surname><given-names>E</given-names></name>, <name><surname>Makinen</surname><given-names>T</given-names></name>, <name><surname>Vitali</surname><given-names>A</given-names></name>, <name><surname>Wilks</surname><given-names>AF</given-names></name>, <etal>et al</etal>
<article-title>Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1998</year>; <volume>95</volume>(<issue>2</issue>):<fpage>548</fpage>&#x02013;<lpage>53</lpage>. Epub 1998/01/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.95.2.548">10.1073/pnas.95.2.548</ext-link></comment> ; PubMed Central PMCID: PMCPmc18457.<pub-id pub-id-type="pmid">9435229</pub-id></mixed-citation></ref><ref id="pone.0163697.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Houck</surname><given-names>KA</given-names></name>, <name><surname>Ferrara</surname><given-names>N</given-names></name>, <name><surname>Winer</surname><given-names>J</given-names></name>, <name><surname>Cachianes</surname><given-names>G</given-names></name>, <name><surname>Li</surname><given-names>B</given-names></name>, <name><surname>Leung</surname><given-names>DW</given-names></name>. <article-title>The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA</article-title>. <source>Mol Endocrinol (Baltimore, Md)</source>. <year>1991</year>; <volume>5</volume>(<issue>12</issue>):<fpage>1806</fpage>&#x02013;<lpage>14</lpage>. Epub 1991/12/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1210/mend-5-12-1806">10.1210/mend-5-12-1806</ext-link></comment> .<pub-id pub-id-type="pmid">1791831</pub-id></mixed-citation></ref><ref id="pone.0163697.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Jilani</surname><given-names>SM</given-names></name>, <name><surname>Nikolova</surname><given-names>GV</given-names></name>, <name><surname>Carpizo</surname><given-names>D</given-names></name>, <name><surname>Iruela-Arispe</surname><given-names>ML</given-names></name>. <article-title>Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors</article-title>. <source>J Cell Biol</source>. <year>2005</year>; <volume>169</volume>(<issue>4</issue>):<fpage>681</fpage>&#x02013;<lpage>91</lpage>. Epub 2005/05/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.200409115">10.1083/jcb.200409115</ext-link></comment> ; PubMed Central PMCID: PMCPmc2171712.<pub-id pub-id-type="pmid">15911882</pub-id></mixed-citation></ref><ref id="pone.0163697.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Delcombel</surname><given-names>R</given-names></name>, <name><surname>Janssen</surname><given-names>L</given-names></name>, <name><surname>Vassy</surname><given-names>R</given-names></name>, <name><surname>Gammons</surname><given-names>M</given-names></name>, <name><surname>Haddad</surname><given-names>O</given-names></name>, <name><surname>Richard</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation</article-title>. <source>Angiogenesis</source>. <year>2013</year>; <volume>16</volume>(<issue>2</issue>):<fpage>353</fpage>&#x02013;<lpage>71</lpage>. Epub 2012/12/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10456-012-9320-y">10.1007/s10456-012-9320-y</ext-link></comment> .<pub-id pub-id-type="pmid">23254820</pub-id></mixed-citation></ref><ref id="pone.0163697.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Vempati</surname><given-names>P</given-names></name>, <name><surname>Popel</surname><given-names>AS</given-names></name>, <name><surname>Mac Gabhann</surname><given-names>F</given-names></name>. <article-title>Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning</article-title>. <source>Cytokine &#x00026; Growth Factor Rev</source>. <year>2014</year>; <volume>25</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>19</lpage>. Epub 2013/12/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cytogfr.2013.11.002">10.1016/j.cytogfr.2013.11.002</ext-link></comment> ; PubMed Central PMCID: PMCPmc3977708.<pub-id pub-id-type="pmid">24332926</pub-id></mixed-citation></ref><ref id="pone.0163697.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Houck</surname><given-names>KA</given-names></name>, <name><surname>Leung</surname><given-names>DW</given-names></name>, <name><surname>Rowland</surname><given-names>AM</given-names></name>, <name><surname>Winer</surname><given-names>J</given-names></name>, <name><surname>Ferrara</surname><given-names>N</given-names></name>. <article-title>Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms</article-title>. <source>J Biol Chem</source>. <year>1992</year>; <volume>267</volume>(<issue>36</issue>):<fpage>26031</fpage>&#x02013;<lpage>7</lpage>. Epub 1992/12/25. .<pub-id pub-id-type="pmid">1464614</pub-id></mixed-citation></ref><ref id="pone.0163697.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Ferrara</surname><given-names>N</given-names></name>, <name><surname>Gerber</surname><given-names>HP</given-names></name>, <name><surname>LeCouter</surname><given-names>J</given-names></name>. <article-title>The biology of VEGF and its receptors</article-title>. <source>Nat Med</source>. <year>2003</year>; <volume>9</volume>(<issue>6</issue>):<fpage>669</fpage>&#x02013;<lpage>76</lpage>. Epub 2003/06/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm0603-669">10.1038/nm0603-669</ext-link></comment> .<pub-id pub-id-type="pmid">12778165</pub-id></mixed-citation></ref><ref id="pone.0163697.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Keyt</surname><given-names>BA</given-names></name>, <name><surname>Berleau</surname><given-names>LT</given-names></name>, <name><surname>Nguyen</surname><given-names>HV</given-names></name>, <name><surname>Chen</surname><given-names>H</given-names></name>, <name><surname>Heinsohn</surname><given-names>H</given-names></name>, <name><surname>Vandlen</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>The carboxyl-terminal domain (111&#x02013;165) of vascular endothelial growth factor is critical for its mitogenic potency</article-title>. <source>J Biol Chem</source>. <year>1996</year>; <volume>271</volume>(<issue>13</issue>):<fpage>7788</fpage>&#x02013;<lpage>95</lpage>. Epub 1996/03/29. .<pub-id pub-id-type="pmid">8631822</pub-id></mixed-citation></ref><ref id="pone.0163697.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Carmeliet</surname><given-names>P</given-names></name>, <name><surname>Ng</surname><given-names>YS</given-names></name>, <name><surname>Nuyens</surname><given-names>D</given-names></name>, <name><surname>Theilmeier</surname><given-names>G</given-names></name>, <name><surname>Brusselmans</surname><given-names>K</given-names></name>, <name><surname>Cornelissen</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188</article-title>. <source>Nat Med</source>. <year>1999</year>; <volume>5</volume>(<issue>5</issue>):<fpage>495</fpage>&#x02013;<lpage>502</lpage>. Epub 1999/05/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/8379">10.1038/8379</ext-link></comment> .<pub-id pub-id-type="pmid">10229225</pub-id></mixed-citation></ref><ref id="pone.0163697.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Arcondeguy</surname><given-names>T</given-names></name>, <name><surname>Lacazette</surname><given-names>E</given-names></name>, <name><surname>Millevoi</surname><given-names>S</given-names></name>, <name><surname>Prats</surname><given-names>H</given-names></name>, <name><surname>Touriol</surname><given-names>C</given-names></name>. <article-title>VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level</article-title>. <source>Nucleic Acids Res</source>. <year>2013</year>; <volume>41</volume>(<issue>17</issue>):<fpage>7997</fpage>&#x02013;<lpage>8010</lpage>. Epub 2013/07/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkt539">10.1093/nar/gkt539</ext-link></comment> ; PubMed Central PMCID: PMCPmc3783158.<pub-id pub-id-type="pmid">23851566</pub-id></mixed-citation></ref><ref id="pone.0163697.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Ruhrberg</surname><given-names>C</given-names></name>, <name><surname>Gerhardt</surname><given-names>H</given-names></name>, <name><surname>Golding</surname><given-names>M</given-names></name>, <name><surname>Watson</surname><given-names>R</given-names></name>, <name><surname>Ioannidou</surname><given-names>S</given-names></name>, <name><surname>Fujisawa</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis</article-title>. <source>Genes &#x00026; Development</source>. <year>2002</year>; <volume>16</volume>(<issue>20</issue>):<fpage>2684</fpage>&#x02013;<lpage>98</lpage>. Epub 2002/10/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gad.242002">10.1101/gad.242002</ext-link></comment> ; PubMed Central PMCID: PMCPmc187458.<pub-id pub-id-type="pmid">12381667</pub-id></mixed-citation></ref><ref id="pone.0163697.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Stalmans</surname><given-names>I</given-names></name>, <name><surname>Ng</surname><given-names>YS</given-names></name>, <name><surname>Rohan</surname><given-names>R</given-names></name>, <name><surname>Fruttiger</surname><given-names>M</given-names></name>, <name><surname>Bouche</surname><given-names>A</given-names></name>, <name><surname>Yuce</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms</article-title>. <source>J Clin Investig</source>. <year>2002</year>; <volume>109</volume>(<issue>3</issue>):<fpage>327</fpage>&#x02013;<lpage>36</lpage>. Epub 2002/02/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/jci14362">10.1172/jci14362</ext-link></comment> ; PubMed Central PMCID: PMCPmc150858.<pub-id pub-id-type="pmid">11827992</pub-id></mixed-citation></ref><ref id="pone.0163697.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Maes</surname><given-names>C</given-names></name>, <name><surname>Stockmans</surname><given-names>I</given-names></name>, <name><surname>Moermans</surname><given-names>K</given-names></name>, <name><surname>Van Looveren</surname><given-names>R</given-names></name>, <name><surname>Smets</surname><given-names>N</given-names></name>, <name><surname>Carmeliet</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival</article-title>. <source>J Clin Investig</source>. <year>2004</year>; <volume>113</volume>(<issue>2</issue>):<fpage>188</fpage>&#x02013;<lpage>99</lpage>. Epub 2004/01/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/jci19383">10.1172/jci19383</ext-link></comment> ; PubMed Central PMCID: PMCPmc312596.<pub-id pub-id-type="pmid">14722611</pub-id></mixed-citation></ref><ref id="pone.0163697.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Ferrara</surname><given-names>N</given-names></name>. <article-title>Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action</article-title>. <source>Mol Biol Cell</source>. <year>2010</year>; <volume>21</volume>(<issue>5</issue>):<fpage>687</fpage>&#x02013;<lpage>90</lpage>. Epub 2010/02/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1091/mbc.E09-07-0590">10.1091/mbc.E09-07-0590</ext-link></comment> ; PubMed Central PMCID: PMCPmc2828956.<pub-id pub-id-type="pmid">20185770</pub-id></mixed-citation></ref><ref id="pone.0163697.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>JE</given-names></name>, <name><surname>Keller</surname><given-names>GA</given-names></name>, <name><surname>Ferrara</surname><given-names>N</given-names></name>. <article-title>The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF</article-title>. <source>Mol Biol Cell</source>. <year>1993</year>; <volume>4</volume>(<issue>12</issue>):<fpage>1317</fpage>&#x02013;<lpage>26</lpage>. Epub 1993/12/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1091/mbc.4.12.1317">10.1091/mbc.4.12.1317</ext-link></comment> ; PubMed Central PMCID: PMCPmc275767.<pub-id pub-id-type="pmid">8167412</pub-id></mixed-citation></ref><ref id="pone.0163697.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Yla-Herttuala</surname><given-names>S</given-names></name>, <name><surname>Rissanen</surname><given-names>TT</given-names></name>, <name><surname>Vajanto</surname><given-names>I</given-names></name>, <name><surname>Hartikainen</surname><given-names>J</given-names></name>. <article-title>Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>; <volume>49</volume>(<issue>10</issue>):<fpage>1015</fpage>&#x02013;<lpage>26</lpage>. Epub 2007/03/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jacc.2006.09.053">10.1016/j.jacc.2006.09.053</ext-link></comment> .<pub-id pub-id-type="pmid">17349880</pub-id></mixed-citation></ref><ref id="pone.0163697.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Hendel</surname><given-names>RC</given-names></name>, <name><surname>Henry</surname><given-names>TD</given-names></name>, <name><surname>Rocha-Singh</surname><given-names>K</given-names></name>, <name><surname>Isner</surname><given-names>JM</given-names></name>, <name><surname>Kereiakes</surname><given-names>DJ</given-names></name>, <name><surname>Giordano</surname><given-names>FJ</given-names></name>, <etal>et al</etal>
<article-title>Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect</article-title>. <source>Circulation</source>. <year>2000</year>; <volume>101</volume>(<issue>2</issue>):<fpage>118</fpage>&#x02013;<lpage>21</lpage>. Epub 2000/01/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/01.CIR.101.2.118">10.1161/01.CIR.101.2.118</ext-link></comment> .<pub-id pub-id-type="pmid">10637195</pub-id></mixed-citation></ref><ref id="pone.0163697.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Rosengart</surname><given-names>TK</given-names></name>, <name><surname>Lee</surname><given-names>LY</given-names></name>, <name><surname>Patel</surname><given-names>SR</given-names></name>, <name><surname>Kligfield</surname><given-names>PD</given-names></name>, <name><surname>Okin</surname><given-names>PM</given-names></name>, <name><surname>Hackett</surname><given-names>NR</given-names></name>, <etal>et al</etal>
<article-title>Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA</article-title>. <source>Annals of Surgery</source>. <year>1999</year>; <volume>230</volume>(<issue>4</issue>):<fpage>466</fpage>&#x02013;<lpage>70</lpage>; discussion 70&#x02013;2. Epub 1999/10/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00000658-199910000-00002">10.1097/00000658-199910000-00002</ext-link></comment> ; PubMed Central PMCID: PMCPmc1420895.<pub-id pub-id-type="pmid">10522716</pub-id></mixed-citation></ref><ref id="pone.0163697.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Simon-Yarza</surname><given-names>T</given-names></name>, <name><surname>Formiga</surname><given-names>FR</given-names></name>, <name><surname>Tamayo</surname><given-names>E</given-names></name>, <name><surname>Pelacho</surname><given-names>B</given-names></name>, <name><surname>Prosper</surname><given-names>F</given-names></name>, <name><surname>Blanco-Prieto</surname><given-names>MJ</given-names></name>. <article-title>Vascular endothelial growth factor-delivery systems for cardiac repair: an overview</article-title>. <source>Theranostics</source>. <year>2012</year>; <volume>2</volume>(<issue>6</issue>):<fpage>541</fpage>&#x02013;<lpage>52</lpage>. Epub 2012/06/28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.7150/thno.3682">10.7150/thno.3682</ext-link></comment> ; PubMed Central PMCID: PMCPmc3381347.<pub-id pub-id-type="pmid">22737191</pub-id></mixed-citation></ref><ref id="pone.0163697.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Gupta</surname><given-names>R</given-names></name>, <name><surname>Tongers</surname><given-names>J</given-names></name>, <name><surname>Losordo</surname><given-names>DW</given-names></name>. <article-title>Human studies of angiogenic gene therapy</article-title>. <source>Circul Res</source>. <year>2009</year>; <volume>105</volume>(<issue>8</issue>):<fpage>724</fpage>&#x02013;<lpage>36</lpage>. Epub 2009/10/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/circresaha.109.200386">10.1161/circresaha.109.200386</ext-link></comment> ; PubMed Central PMCID: PMCPmc2770893.<pub-id pub-id-type="pmid">19815827</pub-id></mixed-citation></ref><ref id="pone.0163697.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Henry</surname><given-names>TD</given-names></name>, <name><surname>Annex</surname><given-names>BH</given-names></name>, <name><surname>McKendall</surname><given-names>GR</given-names></name>, <name><surname>Azrin</surname><given-names>MA</given-names></name>, <name><surname>Lopez</surname><given-names>JJ</given-names></name>, <name><surname>Giordano</surname><given-names>FJ</given-names></name>, <etal>et al</etal>
<article-title>The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis</article-title>. <source>Circulation</source>. <year>2003</year>; <volume>107</volume>(<issue>10</issue>):<fpage>1359</fpage>&#x02013;<lpage>65</lpage>. Epub 2003/03/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/01.CIR.0000061911.47710.8A">10.1161/01.CIR.0000061911.47710.8A</ext-link></comment> .<pub-id pub-id-type="pmid">12642354</pub-id></mixed-citation></ref><ref id="pone.0163697.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Eppler</surname><given-names>SM</given-names></name>, <name><surname>Combs</surname><given-names>DL</given-names></name>, <name><surname>Henry</surname><given-names>TD</given-names></name>, <name><surname>Lopez</surname><given-names>JJ</given-names></name>, <name><surname>Ellis</surname><given-names>SG</given-names></name>, <name><surname>Yi</surname><given-names>JH</given-names></name>, <etal>et al</etal>
<article-title>A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans</article-title>. <source>Clin Pharmacol Therapeutics</source>. <year>2002</year>; <volume>72</volume>(<issue>1</issue>):<fpage>20</fpage>&#x02013;<lpage>32</lpage>. Epub 2002/08/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1067/mcp.2002.126179">10.1067/mcp.2002.126179</ext-link></comment> .<pub-id pub-id-type="pmid">12152001</pub-id></mixed-citation></ref><ref id="pone.0163697.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>K</given-names></name>, <name><surname>Silva</surname><given-names>EA</given-names></name>, <name><surname>Mooney</surname><given-names>DJ</given-names></name>. <article-title>Growth factor delivery-based tissue engineering: general approaches and a review of recent developments</article-title>. <source>J R Soc Interface</source>. <year>2011</year>; <volume>8</volume>(<issue>55</issue>):<fpage>153</fpage>&#x02013;<lpage>70</lpage>. Epub 2010/08/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1098/rsif.2010.0223">10.1098/rsif.2010.0223</ext-link></comment> ; PubMed Central PMCID: PMCPmc3033020.<pub-id pub-id-type="pmid">20719768</pub-id></mixed-citation></ref><ref id="pone.0163697.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Zisch</surname><given-names>AH</given-names></name>, <name><surname>Schenk</surname><given-names>U</given-names></name>, <name><surname>Schense</surname><given-names>JC</given-names></name>, <name><surname>Sakiyama-Elbert</surname><given-names>SE</given-names></name>, <name><surname>Hubbell</surname><given-names>JA</given-names></name>. <article-title>Covalently conjugated VEGF&#x02014;fibrin matrices for endothelialization</article-title>. <source>J Control Release</source>. <year>2001</year>; <volume>72</volume>(<issue>1&#x02013;3</issue>):<fpage>101</fpage>&#x02013;<lpage>13</lpage>. Epub 2001/06/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0168-3659(01)00266-8">10.1016/S0168-3659(01)00266-8</ext-link></comment> .<pub-id pub-id-type="pmid">11389989</pub-id></mixed-citation></ref><ref id="pone.0163697.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>LaVallie</surname><given-names>ER</given-names></name>, <name><surname>DiBlasio</surname><given-names>EA</given-names></name>, <name><surname>Kovacic</surname><given-names>S</given-names></name>, <name><surname>Grant</surname><given-names>KL</given-names></name>, <name><surname>Schendel</surname><given-names>PF</given-names></name>, <name><surname>McCoy</surname><given-names>JM</given-names></name>. <article-title>A thioredoxin gene fusion expression system that circumvents inclusion body formation in the <italic>E</italic>. <italic>coli</italic> cytoplasm</article-title>. <source>Bio-Technology</source>. <year>1993</year>; <volume>11</volume>(<issue>2</issue>):<fpage>187</fpage>&#x02013;<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nbt0293-187">10.1038/nbt0293-187</ext-link></comment>
<pub-id pub-id-type="pmid">7763371</pub-id></mixed-citation></ref><ref id="pone.0163697.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>LaVallie</surname><given-names>ER</given-names></name>, <name><surname>McCoy</surname><given-names>JM</given-names></name>. <article-title>Gene fusion expression systems in <italic>Escherichia coli</italic></article-title>. <source>Curr Opin in Biotechnol</source>. <year>1995</year>; <volume>6</volume>(<issue>5</issue>):<fpage>501</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0958-1669(95)80083-2">10.1016/0958-1669(95)80083-2</ext-link></comment></mixed-citation></ref><ref id="pone.0163697.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Costa</surname><given-names>SJ</given-names></name>, <name><surname>Almeida</surname><given-names>A</given-names></name>, <name><surname>Castro</surname><given-names>A</given-names></name>, <name><surname>Domingues</surname><given-names>L</given-names></name>, <name><surname>Besir</surname><given-names>H</given-names></name>. <article-title>The novel Fh8 and H fusion partners for soluble protein expression in <italic>Escherichia coli</italic>: a comparison with the traditional gene fusion technology</article-title>. <source>Appl Microbiol Biotechnol</source>. <year>2013</year>; <volume>97</volume>(<issue>15</issue>):<fpage>6779</fpage>&#x02013;<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00253-012-4559-1">10.1007/s00253-012-4559-1</ext-link></comment> .<pub-id pub-id-type="pmid">23160981</pub-id></mixed-citation></ref><ref id="pone.0163697.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Sachdev</surname><given-names>D</given-names></name>, <name><surname>Chirgwin</surname><given-names>JM</given-names></name>. <article-title>Solubility of proteins isolated from inclusion bodies is enhanced by fusion to maltose-binding protein or thioredoxin</article-title>. <source>Protein Expr Purif</source>. <year>1998</year>; <volume>12</volume>(<issue>1</issue>):<fpage>122</fpage>&#x02013;<lpage>32</lpage>. Epub 1998/03/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1006/prep.1997.0826">10.1006/prep.1997.0826</ext-link></comment> .<pub-id pub-id-type="pmid">9473466</pub-id></mixed-citation></ref><ref id="pone.0163697.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>An</surname><given-names>N</given-names></name>, <name><surname>Kang</surname><given-names>Y</given-names></name>. <article-title>Thioredoxin and hematologic malignancies</article-title>. <source>Adv Cancer Res</source>. <year>2014</year>; <volume>122</volume>:<fpage>245</fpage>&#x02013;<lpage>79</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/B978-0-12-420117-0.00007-4">10.1016/B978-0-12-420117-0.00007-4</ext-link></comment> .<pub-id pub-id-type="pmid">24974184</pub-id></mixed-citation></ref><ref id="pone.0163697.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Matsushima</surname><given-names>S</given-names></name>, <name><surname>Zablocki</surname><given-names>D</given-names></name>, <name><surname>Sadoshima</surname><given-names>J</given-names></name>. <article-title>Application of recombinant thioredoxin1 for treatment of heart disease</article-title>. <source>J Mol Cell Cardiol</source>. <year>2011</year>; <volume>51</volume>(<issue>4</issue>):<fpage>570</fpage>&#x02013;<lpage>3</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yjmcc.2010.09.020">10.1016/j.yjmcc.2010.09.020</ext-link></comment> ; PubMed Central PMCID: PMCPMC3034160.<pub-id pub-id-type="pmid">20955713</pub-id></mixed-citation></ref><ref id="pone.0163697.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Dunn</surname><given-names>LL</given-names></name>, <name><surname>Buckle</surname><given-names>AM</given-names></name>, <name><surname>Cooke</surname><given-names>JP</given-names></name>, <name><surname>Ng</surname><given-names>MK</given-names></name>. <article-title>The emerging role of the thioredoxin system in angiogenesis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2010</year>; <volume>30</volume>(<issue>11</issue>):<fpage>2089</fpage>&#x02013;<lpage>98</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/ATVBAHA.110.209643">10.1161/ATVBAHA.110.209643</ext-link></comment> ; PubMed Central PMCID: PMCPMC3142174.<pub-id pub-id-type="pmid">20798378</pub-id></mixed-citation></ref><ref id="pone.0163697.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>S</given-names></name>, <name><surname>Mohamedali</surname><given-names>KA</given-names></name>, <name><surname>Cheung</surname><given-names>LH</given-names></name>, <name><surname>Rosenblum</surname><given-names>MG</given-names></name>. <article-title>Overexpression of biologically active VEGF121 fusion proteins in <italic>Escherichia coli</italic></article-title>. <source>J Biotechnol</source>. <year>2007</year>; <volume>128</volume>(<issue>3</issue>):<fpage>638</fpage>&#x02013;<lpage>47</lpage>. Epub 2007/01/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jbiotec.2006.11.027">10.1016/j.jbiotec.2006.11.027</ext-link></comment> .<pub-id pub-id-type="pmid">17218033</pub-id></mixed-citation></ref><ref id="pone.0163697.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Gasparian</surname><given-names>ME</given-names></name>, <name><surname>Elistratov</surname><given-names>PA</given-names></name>, <name><surname>Drize</surname><given-names>NI</given-names></name>, <name><surname>Nifontova</surname><given-names>IN</given-names></name>, <name><surname>Dolgikh</surname><given-names>DA</given-names></name>, <name><surname>Kirpichnikov</surname><given-names>MP</given-names></name>. <article-title>Overexpression in <italic>Escherichia coli</italic> and purification of human fibroblast growth factor (FGF-2)</article-title>. <source>Biochemistry (Mosc)</source>. <year>2009</year>; <volume>74</volume>(<issue>2</issue>):<fpage>221</fpage>&#x02013;<lpage>5</lpage>. Epub 2009/03/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1134/S000629790902014X">10.1134/S000629790902014X</ext-link></comment> .<pub-id pub-id-type="pmid">19267679</pub-id></mixed-citation></ref><ref id="pone.0163697.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Xiong</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>YF</given-names></name>, <name><surname>Ren</surname><given-names>XR</given-names></name>, <name><surname>Li</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>MY</given-names></name>, <name><surname>Luo</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Solubility of disulfide-bonded proteins in the cytoplasm of <italic>Escherichia coli</italic> and its "oxidizing" mutant</article-title>. <source>World J Gastroenter (WJG)</source>. <year>2005</year>; <volume>11</volume>(<issue>7</issue>):<fpage>1077</fpage>&#x02013;<lpage>82</lpage>. Epub 2005/03/03. ; PubMed Central PMCID: PMCPmc4250777.<pub-id pub-id-type="pmid">15742420</pub-id></mixed-citation></ref><ref id="pone.0163697.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>HS</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <name><surname>Runge</surname><given-names>MS</given-names></name>, <name><surname>Chaikof</surname><given-names>EL</given-names></name>. <article-title>Endothelial cells exhibit differential chemokinetic and mitogenic responsiveness to alpha-thrombin</article-title>. <source>J Surg Res</source>. <year>1997</year>; <volume>68</volume>(<issue>2</issue>):<fpage>139</fpage>&#x02013;<lpage>44</lpage>. Epub 1997/03/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1006/jsre.1997.5044">10.1006/jsre.1997.5044</ext-link></comment> .<pub-id pub-id-type="pmid">9184672</pub-id></mixed-citation></ref><ref id="pone.0163697.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Zucker</surname><given-names>S</given-names></name>, <name><surname>Mirza</surname><given-names>H</given-names></name>, <name><surname>Conner</surname><given-names>CE</given-names></name>, <name><surname>Lorenz</surname><given-names>AF</given-names></name>, <name><surname>Drews</surname><given-names>MH</given-names></name>, <name><surname>Bahou</surname><given-names>WF</given-names></name>, <etal>et al</etal>
<article-title>Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation</article-title>. <source>Int J Cancer</source>. <year>1998</year>; <volume>75</volume>(<issue>5</issue>):<fpage>780</fpage>&#x02013;<lpage>6</lpage>. Epub 1998/03/12. .<pub-id pub-id-type="pmid">9495249</pub-id></mixed-citation></ref><ref id="pone.0163697.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Borrelli</surname><given-names>V</given-names></name>, <name><surname>Sterpetti</surname><given-names>AV</given-names></name>, <name><surname>Coluccia</surname><given-names>P</given-names></name>, <name><surname>Randone</surname><given-names>B</given-names></name>, <name><surname>Cavallaro</surname><given-names>A</given-names></name>, <name><surname>Santoro D'Angelo</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Bimodal concentration-dependent effect of thrombin on endothelial cell proliferation and growth factor release in culture</article-title>. <source>J Surg Res</source>. <year>2001</year>; <volume>100</volume>(<issue>2</issue>):<fpage>154</fpage>&#x02013;<lpage>60</lpage>. Epub 2001/10/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1006/jsre.2001.6231">10.1006/jsre.2001.6231</ext-link></comment> .<pub-id pub-id-type="pmid">11592785</pub-id></mixed-citation></ref><ref id="pone.0163697.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>TB</given-names></name>, <name><surname>Yang</surname><given-names>GS</given-names></name>. <article-title>Roles of vascular endothelial growth factor in acute rejection reaction following liver transplantation</article-title>. <source>Transpl Immunol</source>. <year>2011</year>;<volume>25</volume>(<issue>4</issue>):<fpage>207</fpage>&#x02013;<lpage>9</lpage>. Epub 2011 Aug 11. ; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.trim.2011.08.001">10.1016/j.trim.2011.08.001</ext-link></comment><pub-id pub-id-type="pmid">21856421</pub-id></mixed-citation></ref><ref id="pone.0163697.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Dormond</surname><given-names>O</given-names></name>, <name><surname>Dufour</surname><given-names>M</given-names></name>, <name><surname>Seto</surname><given-names>T</given-names></name>, <name><surname>Bruneau</surname><given-names>S</given-names></name>, <name><surname>Briscoe</surname><given-names>DM</given-names></name>. <article-title>Targeting the intragraft microenvironment and the development of chronic allograft rejection</article-title>. <source>Hum Immunol</source>. <year>2012</year>;<volume>73</volume>(<issue>12</issue>):<fpage>1261</fpage>&#x02013;<lpage>8</lpage>. Epub 2012 Aug 3. ; PMCID: PMC3496805; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.humimm.2012.07.334">10.1016/j.humimm.2012.07.334</ext-link></comment><pub-id pub-id-type="pmid">22863981</pub-id></mixed-citation></ref><ref id="pone.0163697.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Bradford</surname><given-names>MM</given-names></name>. <article-title>A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding</article-title>. <source>Anal Biochem</source>. <year>1976</year>; <volume>72</volume>:<fpage>248</fpage>&#x02013;<lpage>54</lpage>. Epub 1976/05/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0003-2697(76)90527-3">10.1016/0003-2697(76)90527-3</ext-link></comment> .<pub-id pub-id-type="pmid">942051</pub-id></mixed-citation></ref><ref id="pone.0163697.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Parizek</surname><given-names>M</given-names></name>, <name><surname>Douglas</surname><given-names>TE</given-names></name>, <name><surname>Novotna</surname><given-names>K</given-names></name>, <name><surname>Kromka</surname><given-names>A</given-names></name>, <name><surname>Brady</surname><given-names>MA</given-names></name>, <name><surname>Renzing</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Nanofibrous poly(lactide-co-glycolide) membranes loaded with diamond nanoparticles as promising substrates for bone tissue engineering</article-title>. <source>Int J Nanomedicine</source>. <year>2012</year>;<volume>7</volume>:<fpage>1931</fpage>&#x02013;<lpage>51</lpage>. Epub 2012 Apr 17. ; PMCID: PMC3356197; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/IJN.S26665">10.2147/IJN.S26665</ext-link></comment><pub-id pub-id-type="pmid">22619532</pub-id></mixed-citation></ref><ref id="pone.0163697.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Scrofani</surname><given-names>SD</given-names></name>, <name><surname>Fabri</surname><given-names>LJ</given-names></name>, <name><surname>Xu</surname><given-names>P</given-names></name>, <name><surname>Maccarone</surname><given-names>P</given-names></name>, <name><surname>Nash</surname><given-names>AD</given-names></name>. <article-title>Purification and refolding of vascular endothelial growth factor-B</article-title>. <source>Protein Sci</source>. <year>2000</year>; <volume>9</volume>(<issue>10</issue>):<fpage>2018</fpage>&#x02013;<lpage>25</lpage>. Epub 2000/12/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1110/ps.9.10.2018">10.1110/ps.9.10.2018</ext-link></comment> ; PubMed Central PMCID: PMCPMC2144466.<pub-id pub-id-type="pmid">11106176</pub-id></mixed-citation></ref><ref id="pone.0163697.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Backer</surname><given-names>MV</given-names></name>, <name><surname>Backer</surname><given-names>JM</given-names></name>. <article-title>Functionally active VEGF fusion proteins</article-title>. <source>Protein Expr Purif</source>. <year>2001</year>; <volume>23</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>7</lpage>. Epub 2001/09/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1006/prep.2001.1472">10.1006/prep.2001.1472</ext-link></comment> .<pub-id pub-id-type="pmid">11570839</pub-id></mixed-citation></ref><ref id="pone.0163697.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Morera</surname><given-names>Y</given-names></name>, <name><surname>Lamdan</surname><given-names>H</given-names></name>, <name><surname>Bequet</surname><given-names>M</given-names></name>, <name><surname>Ayala</surname><given-names>M</given-names></name>, <name><surname>Rojas</surname><given-names>G</given-names></name>, <name><surname>Munoz</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Biologically active vascular endothelial growth factor as a bacterial recombinant glutathione S-transferase fusion protein</article-title>. <source>Biotechnology and Appl Biochem</source>. <year>2006</year>; <volume>44</volume>(<issue>1</issue>):<fpage>45</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/ba20050169">10.1042/ba20050169</ext-link>.</comment> PubMed WOS:000236451200006. <pub-id pub-id-type="pmid">16401185</pub-id></mixed-citation></ref><ref id="pone.0163697.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Pizarro</surname><given-names>SA</given-names></name>, <name><surname>Gunson</surname><given-names>J</given-names></name>, <name><surname>Field</surname><given-names>MJ</given-names></name>, <name><surname>Dinges</surname><given-names>R</given-names></name>, <name><surname>Khoo</surname><given-names>S</given-names></name>, <name><surname>Dalal</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>High-yield expression of human vascular endothelial growth factor VEGF(165) in <italic>Escherichia coli</italic> and purification for therapeutic applications</article-title>. <source>Protein Expr Purif</source>. <year>2010</year>; <volume>72</volume>(<issue>2</issue>):<fpage>184</fpage>&#x02013;<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.pep.2010.03.007">10.1016/j.pep.2010.03.007</ext-link></comment> .<pub-id pub-id-type="pmid">20302942</pub-id></mixed-citation></ref><ref id="pone.0163697.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>IL</given-names></name>, <name><surname>Li</surname><given-names>PS</given-names></name>, <name><surname>Yu</surname><given-names>WL</given-names></name>, <name><surname>Shen</surname><given-names>HH</given-names></name>. <article-title>Prokaryotic expression, refolding, and purification of functional human vascular endothelial growth factor isoform 165: purification procedures and refolding conditions revisited</article-title>. <source>Protein Expr Purif</source>. <year>2011</year>; <volume>76</volume>(<issue>1</issue>):<fpage>54</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.pep.2010.08.014">10.1016/j.pep.2010.08.014</ext-link></comment> .<pub-id pub-id-type="pmid">20826215</pub-id></mixed-citation></ref><ref id="pone.0163697.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Kazemi-Lomedasht</surname><given-names>F</given-names></name>, <name><surname>Behdani</surname><given-names>M</given-names></name>, <name><surname>Pooshang Bagheri</surname><given-names>K</given-names></name>, <name><surname>Habibi Anbouhi</surname><given-names>M</given-names></name>, <name><surname>Abolhassani</surname><given-names>M</given-names></name>, <name><surname>Khanahmad</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Expression and purification of functional human vascular endothelial growth factor-a121; the most important angiogenesis factor</article-title>. <source>Adv Pharmaceut Bull</source>. <year>2014</year>; <volume>4</volume>(<issue>4</issue>):<fpage>323</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5681/apb.2014.047">10.5681/apb.2014.047</ext-link>.</comment>
<pub-id pub-id-type="pmid">25436186</pub-id></mixed-citation></ref><ref id="pone.0163697.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Kang</surname><given-names>W</given-names></name>, <name><surname>Kim</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Jeon</surname><given-names>E</given-names></name>, <name><surname>Lee</surname><given-names>Y</given-names></name>, <name><surname>Yun</surname><given-names>YR</given-names></name>, <etal>et al</etal>
<article-title>Characterization and optimization of vascular endothelial growth factor(165) (rhVEGF(165)) expression in <italic>Escherichia coli</italic></article-title>. <source>Protein Expr Purif</source>. <year>2013</year>; <volume>87</volume>(<issue>2</issue>):<fpage>55</fpage>&#x02013;<lpage>60</lpage>. Epub 2012/10/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.pep.2012.10.004">10.1016/j.pep.2012.10.004</ext-link></comment> .<pub-id pub-id-type="pmid">23108225</pub-id></mixed-citation></ref><ref id="pone.0163697.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Heiring</surname><given-names>C</given-names></name>, <name><surname>Muller</surname><given-names>YA</given-names></name>. <article-title>Folding screening assayed by proteolysis: application to various cystine deletion mutants of vascular endothelial growth factor</article-title>. <source>Protein Eng</source>. <year>2001</year>; <volume>14</volume>(<issue>3</issue>):<fpage>183</fpage>&#x02013;<lpage>8</lpage>. Epub 2001/05/09. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/protein/14.3.183">10.1093/protein/14.3.183</ext-link></comment> .<pub-id pub-id-type="pmid">11342715</pub-id></mixed-citation></ref><ref id="pone.0163697.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Petrickova</surname><given-names>A</given-names></name>, <name><surname>Vesela</surname><given-names>AB</given-names></name>, <name><surname>Kaplan</surname><given-names>O</given-names></name>, <name><surname>Kubac</surname><given-names>D</given-names></name>, <name><surname>Uhnakova</surname><given-names>B</given-names></name>, <name><surname>Malandra</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Purification and characterization of heterologously expressed nitrilases from filamentous fungi</article-title>. <source>Appl Microbiol Biotechnol</source>. <year>2012</year>; <volume>93</volume>(<issue>4</issue>):<fpage>1553</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00253-011-3525-7">10.1007/s00253-011-3525-7</ext-link></comment> .<pub-id pub-id-type="pmid">21892598</pub-id></mixed-citation></ref><ref id="pone.0163697.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Maeng</surname><given-names>BH</given-names></name>, <name><surname>Nam</surname><given-names>DH</given-names></name>, <name><surname>Kim</surname><given-names>YH</given-names></name>. <article-title>Coexpression of molecular chaperones to enhance functional expression of anti-BNP scFv in the cytoplasm of <italic>Escherichia coli</italic> for the detection of B-type natriuretic peptide</article-title>. <source>World J Microbiol Biotechnol</source>. <year>2011</year>; <volume>27</volume>(<issue>6</issue>):<fpage>1391</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11274-010-0590-5">10.1007/s11274-010-0590-5</ext-link></comment> .<pub-id pub-id-type="pmid">25187138</pub-id></mixed-citation></ref><ref id="pone.0163697.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>F</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Du</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>S</given-names></name>. <article-title>Overexpression and characterization of a glucose-tolerant beta-glucosidase from <italic>T</italic>. <italic>aotearoense</italic> with high specific activity for cellobiose</article-title>. <source>Appl Microbiol Biotechnol</source>. <year>2015</year>; <volume>99</volume>(<issue>21</issue>):<fpage>8903</fpage>&#x02013;<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00253-015-6619-9">10.1007/s00253-015-6619-9</ext-link></comment> .<pub-id pub-id-type="pmid">25957152</pub-id></mixed-citation></ref><ref id="pone.0163697.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Rodrigo</surname><given-names>WW</given-names></name>, <name><surname>Dassanayake</surname><given-names>RS</given-names></name>, <name><surname>Karunanayake</surname><given-names>EH</given-names></name>, <name><surname>Gunawardene</surname><given-names>YINS</given-names></name>, <name><surname>Weerasena</surname><given-names>OVJ</given-names></name>. <article-title>Heterologous expression, chaperone mediated solubilization and purification of parasitic nematode&#x02013;specific growth factor&#x02013;like protein of <italic>Setaria digitata</italic></article-title>. <source>Asian Pacific J Tropical Med</source>. <year>2014</year>; <volume>7</volume>(<issue>2</issue>):<fpage>85</fpage>&#x02013;<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/s1995-7645(14)60001-8">10.1016/s1995-7645(14)60001-8</ext-link></comment>
<pub-id pub-id-type="pmid">24461519</pub-id></mixed-citation></ref><ref id="pone.0163697.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Pfeffer</surname><given-names>J</given-names></name>, <name><surname>Rusnak</surname><given-names>M</given-names></name>, <name><surname>Hansen</surname><given-names>C-E</given-names></name>, <name><surname>Rhlid</surname><given-names>RB</given-names></name>, <name><surname>Schmid</surname><given-names>RD</given-names></name>, <name><surname>Maurer</surname><given-names>SC</given-names></name>. <article-title>Functional expression of lipase A from <italic>Candida antarctica</italic> in <italic>Escherichia coli</italic>&#x02014;A prerequisite for high-throughput screening and directed evolution</article-title>. <source>J Mol Catalysis B: Enzymatic</source>. <year>2007</year>; <volume>45</volume>(<issue>1&#x02013;2</issue>):<fpage>62</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molcatb.2006.11.006">10.1016/j.molcatb.2006.11.006</ext-link></comment></mixed-citation></ref><ref id="pone.0163697.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Sonoda</surname><given-names>H</given-names></name>, <name><surname>Kumada</surname><given-names>Y</given-names></name>, <name><surname>Katsuda</surname><given-names>T</given-names></name>, <name><surname>Yamaji</surname><given-names>H</given-names></name>. <article-title>Functional expression of single-chain Fv antibody in the cytoplasm of <italic>Escherichia coli</italic> by thioredoxin fusion and co-expression of molecular chaperones</article-title>. <source>Protein Expr Purif</source>. <year>2010</year>; <volume>70</volume>(<issue>2</issue>):<fpage>248</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.pep.2009.11.003">10.1016/j.pep.2009.11.003</ext-link></comment>
<pub-id pub-id-type="pmid">19913620</pub-id></mixed-citation></ref><ref id="pone.0163697.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Mitsuda</surname><given-names>M</given-names></name>, <name><surname>Iwasaki</surname><given-names>M</given-names></name>. <article-title>Improvement in the expression of CYP2B6 by co-expression with molecular chaperones GroES/EL in <italic>Escherichia coli</italic></article-title>. <source>Protein Expr Purif</source>. <year>2006</year>; <volume>46</volume>(<issue>2</issue>):<fpage>401</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.pep.2005.10.017">10.1016/j.pep.2005.10.017</ext-link></comment> .<pub-id pub-id-type="pmid">16310378</pub-id></mixed-citation></ref><ref id="pone.0163697.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>ZM</given-names></name>, <name><surname>Ma</surname><given-names>L</given-names></name>, <name><surname>Zhou</surname><given-names>MQ</given-names></name>, <name><surname>Gao</surname><given-names>JM</given-names></name>, <name><surname>Wang</surname><given-names>XN</given-names></name>. <article-title>Refolding and purification of recombinant human VEGF-121 expressed as inclusion bodies in <italic>Escherichia coli</italic></article-title>. <source>Nan Fang Yike Daxue Xuebao.</source>
<year>2006</year>; <volume>26</volume>(<issue>8</issue>):<fpage>1083</fpage>&#x02013;<lpage>6</lpage>. Epub 2006/08/31. .<pub-id pub-id-type="pmid">16939889</pub-id></mixed-citation></ref><ref id="pone.0163697.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Suresh</surname><given-names>SC</given-names></name>, <name><surname>Selvaraju</surname><given-names>V</given-names></name>, <name><surname>Thirunavukkarasu</surname><given-names>M</given-names></name>, <name><surname>Goldman</surname><given-names>JW</given-names></name>, <name><surname>Husain</surname><given-names>A</given-names></name>, <name><surname>Alexander Palesty</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium</article-title>. <source>Int J Cardiol</source>. <year>2015</year>; <volume>201</volume>(<issue>Dec</issue>):<fpage>517</fpage>&#x02013;<lpage>28</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijcard.2015.08.117">10.1016/j.ijcard.2015.08.117</ext-link></comment> .<pub-id pub-id-type="pmid">26322599</pub-id></mixed-citation></ref><ref id="pone.0163697.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Gasdaska</surname><given-names>JR</given-names></name>, <name><surname>Berggren</surname><given-names>M</given-names></name>, <name><surname>Powis</surname><given-names>G</given-names></name>. <article-title>Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism</article-title>. <source>Cell Growth &#x00026; Differentiation</source>. <year>1995</year>; <volume>6</volume>(<issue>12</issue>):<fpage>1643</fpage>&#x02013;<lpage>50</lpage>. Epub 1995/12/01. .<pub-id pub-id-type="pmid">9019170</pub-id></mixed-citation></ref><ref id="pone.0163697.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Shuo-shuo</surname><given-names>C</given-names></name>, <name><surname>Xue-zheng</surname><given-names>L</given-names></name>, <name><surname>Ji-hong</surname><given-names>S</given-names></name>. <article-title>Effects of co-expression of molecular chaperones on heterologous soluble expression of the cold-active lipase Lip-948</article-title>. <source>Protein Expr Purif</source>. <year>2011</year>; <volume>77</volume>(<issue>2</issue>):<fpage>166</fpage>&#x02013;<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.pep.2011.01.009">10.1016/j.pep.2011.01.009</ext-link></comment> .<pub-id pub-id-type="pmid">21272645</pub-id></mixed-citation></ref><ref id="pone.0163697.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Morera</surname><given-names>Y</given-names></name>, <name><surname>Bequet-Romero</surname><given-names>M</given-names></name>, <name><surname>Ayala</surname><given-names>M</given-names></name>, <name><surname>Velazco</surname><given-names>JC</given-names></name>, <name><surname>P&#x000e9;rez</surname><given-names>PP</given-names></name>, <name><surname>Alba</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates</article-title>. <source>Vaccine</source>. <year>2010</year>;<volume>28</volume>(<issue>19</issue>):<fpage>3453</fpage>&#x02013;<lpage>61</lpage>. Epub 2010 Mar 1. ; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2010.02.069">10.1016/j.vaccine.2010.02.069</ext-link></comment><pub-id pub-id-type="pmid">20197134</pub-id></mixed-citation></ref><ref id="pone.0163697.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>P&#x000e9;rez</surname><given-names>SL</given-names></name>, <name><surname>Morera</surname><given-names>DY</given-names></name>, <name><surname>Bequet-Romero</surname><given-names>M</given-names></name>, <name><surname>Ramses</surname><given-names>HG</given-names></name>, <name><surname>Rodr&#x000ed;guez</surname><given-names>Y</given-names></name>, <name><surname>Castro</surname><given-names>VJ</given-names></name>, <etal>et al</etal>
<article-title>Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate</article-title>. <source>Hum Vaccin Immunother</source>. <year>2015</year>;<volume>11</volume>(<issue>8</issue>):<fpage>2030</fpage>&#x02013;<lpage>7</lpage>. ; PMCID: PMC4635891; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/21645515.2015.1029213">10.1080/21645515.2015.1029213</ext-link></comment><pub-id pub-id-type="pmid">25891359</pub-id></mixed-citation></ref><ref id="pone.0163697.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Gavilondo</surname><given-names>JV</given-names></name>, <name><surname>Hern&#x000e1;ndez-Bernal</surname><given-names>F</given-names></name>, <name><surname>Ayala-&#x000c1;vila</surname><given-names>M</given-names></name>, <name><surname>de la Torre</surname><given-names>AV</given-names></name>, <name><surname>de la Torre</surname><given-names>J</given-names></name>, <name><surname>Morera-D&#x000ed;az</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>19</issue>):<fpage>2241</fpage>&#x02013;<lpage>50</lpage>. Epub 2014 Feb 11. ; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2013.11.102">10.1016/j.vaccine.2013.11.102</ext-link></comment><pub-id pub-id-type="pmid">24530151</pub-id></mixed-citation></ref></ref-list></back></article>